Pharmacovigilance Risk Assessment Committee (PRAC)
Draft agenda for the meeting on 06-09 April 2021

Chair: Sabine Straus – Vice-Chair: Martin Huber

06 April 2021, 10:30 – 19:30, via teleconference
07 April 2021, 08:30 – 19:30, via teleconference
08 April 2021, 08:30 – 19:30, via teleconference
09 April 2021, 08:30 – 16:00, via teleconference

Organisational, regulatory and methodological matters (ORGAM)
22 April 2021, 09:00 – 12:00, via teleconference

Disclaimers
Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also change during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised.

Of note, this agenda is a working document primarily designed for PRAC members and the work the Committee undertakes.

Note on access to documents
Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006, Rev. 1).
# Table of contents

1. Introduction  
1.1. Welcome and declarations of interest of members, alternates and experts ........ 10  
1.2. Agenda of the meeting on 06-09 April 2021.................................................. 10  
1.3. Minutes of the previous meeting on 08-11 March 2021................................. 10

2. EU referral procedures for safety reasons: urgent EU procedures  10  
2.1. Newly triggered procedures........................................................................... 10  
2.2. Ongoing procedures.................................................................................... 10  
2.3. Procedures for finalisation............................................................................. 10

3. EU referral procedures for safety reasons: other EU referral procedures  10  
3.1. Newly triggered procedures........................................................................... 10  
3.2. Ongoing procedures.................................................................................... 10  
3.3. Procedures for finalisation............................................................................. 11  
3.4. Re-examination procedures.......................................................................... 11  
3.5. Others ......................................................................................................... 11

4. Signals assessment and prioritisation  11  
4.1. New signals detected from EU spontaneous reporting systems .................. 11  
4.1.2. Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (previously COVID-19 VACCINE ASTRazeneca) (CAP) ...................... 11  
4.1.3. Fluoroquinolones: ciprofloxacin (NAP); delafloxacin - QUOFENIX (CAP); levofloxacin - QUINSAIR (CAP); lomefloxacin (NAP); moxifloxacin (NAP); norfloxacin (NAP); ofloxacin (NAP); pefloxacin (NAP); prulifloxacin (NAP); rufloxacin (NAP) ........................................................................ 11  
4.1.4. Pembrolizumab – KEYTRUDA (CAP)......................................................... 12  
4.1.5. Piperacillin (NAP); piperacillin, tazobactam (NAP)...................................... 12  
4.2. New signals detected from other sources....................................................... 12  
4.3. Signals follow-up and prioritisation............................................................... 12  
4.3.1. Azathioprine (NAP). .................................................................................. 12  
4.3.2. Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (previously COVID-19 VACCINE ASTRazeneca) (CAP) - EMEA/H/C/005675/SDA/035 ............................................. 13  
4.4. Variation procedure(s) resulting from signal evaluation .............................. 13

5. Risk management plans (RMPs)  13  
5.1. Medicines in the pre-authorisation phase...................................................... 13  
5.1.1. Bimekizumab - EMEA/H/C/005316 ......................................................... 13  
5.1.2. Eladocagene exuparvovec - EMEA/H/C/005352, Orphan ......................... 13
5.2.2. Elosulfase alfa – VIMIZIM (CAP) – EMEA/H/C/002779/II/0034, Orphan .... 14
5.2.3. Ibritumomab tiuxetan – ZEVALIN (CAP) – EMEA/H/C/000547/II/0053 ...... 15
5.2.4. Neratinib – NERLYNX (CAP) – EMEA/H/C/004030/II/0020 .......... 15
5.2.6. Tolvaptan – JINARC (CAP) – EMEA/H/C/002788/II/0029 .......... 16
5.3. Medicines in the post-authorisation phase – CHMP-led procedures .......... 16
5.3.1. Alpelisib – PIQRAY (CAP) – EMEA/H/C/004804/II/0005/G .......... 16
5.3.2. Axicabtagene ciloleucel – YESCARTA (CAP) – EMEA/H/C/004480/II/0028, Orphan .......... 16
5.3.3. Belatacept – NULOJIX (CAP) – EMEA/H/C/002098/II/0070 .......... 17
5.3.4. Budesonide, formoterol – BIRESP SPIROMAX (CAP) – EMEA/H/C/003890/II/0033/G .... 17
5.3.5. Budesonide, formoterol – DUORESP SPIROMAX (CAP) – EMEA/H/C/002348/II/0033/G .... 17
5.3.6. Burosumod – CRYSVITA (CAP) – EMEA/H/C/004275/II/0023, Orphan..... 18
5.3.8. Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) – VAXZEVRIA (previously COVID-19 VACCINE ASTRazeneca) (CAP) – EMEA/H/C/005675/II/0002 .......... 19
5.3.9. COVID-19 mRNA vaccine (nucleoside-modified) – COMIRNATY (CAP) – EMEA/H/C/005735/II/0019 .......... 19
5.3.11. Empagliflozin – JARDIANCE (CAP) – EMEA/H/C/002677/II/0055 .......... 20
5.3.15. Lomitapide – LOJUXTA (CAP) – EMEA/H/C/002578/II/0046 .......... 21
5.3.17. Pertuzumab – PERJETA (CAP) – EMEA/H/C/002547/II/0054 .......... 22
5.3.18. Pirfenidone – ESBRIET (CAP) – EMEA/H/C/002154/II/0069 .......... 22
5.3.20. Raltegravir – ISENTRESS (CAP) – EMEA/H/C/000860/II/0093 .......... 22
5.3.22. Rufioctocog alfa pegol – ADYNOVI (CAP) – EMEA/H/C/004195/X/0018 .......... 23
5.3.23. Sodium phenylbutyrate – PHEBURANE (CAP) – EMEA/H/C/002500/X/0026 .......... 23
6. **Periodic safety update reports (PSURs)**  

**6.1. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) only**

6.1.1. Alemtuzumab - LEMTRADA (CAP) - PSUSA/00010055/202009 (with RMP) ........................................ 25
6.1.2. Avelumab - BAVENCIO (CAP) - PSUSA/00010635/202009 ................................................................. 25
6.1.3. Azilsartan medoxomil - EDARBI (CAP) - PSUSA/00000280/202008 ........................................ 25
6.1.4. Bedaquiline - SIRTURO (CAP) - PSUSA/00010074/202009 ................................................................. 25
6.1.5. Caplacizumab - CABLIVI (CAP) - PSUSA/00010713/202008 ................................................................. 25
6.1.6. Cholic acid - ORPHACOL (CAP) - PSUSA/00010208/202009 ................................................................. 26
6.1.7. Ciclosporin - IKERVIS (CAP); VERKAZIA (CAP) - PSUSA/00010362/202009 .............................. 26
6.1.8. Damoctocog alfa pegol - JIVI (CAP) - PSUSA/00010732/202008 ................................................................. 26
6.1.9. Darunavir, cobicistat, emtricitabine, tenofovir alafenamide - SYMUZA (CAP) - PSUSA/00010646/202009 ................................................................. 26
6.1.10. Darvadstrocel - ALOFISEL (CAP) - PSUSA/00010676/202009 ................................................................. 26
6.1.11. Doravirine - PIFELTRO (CAP) - PSUSA/00010729/202008 ................................................................. 27
6.1.12. Doravirine, lamivudine, tenofovir disoproxil - DELSTRIGO (CAP) - PSUSA/00010731/20200827
6.1.13. Dulaglutide - TRULICITY (CAP) - PSUSA/00010311/202009 ................................................................. 27
6.1.15. Emtricitabine, rilpivirine, tenofovir disoproxil - EVIPLERA (CAP) - PSUSA/00009142/20200827
6.1.16. Enzalutamide - XTANDI (CAP) - PSUSA/00010095/202008 ................................................................. 27
6.1.17. Esketamine - SPRAVATO (CAP) - PSUSA/00010825/202009 ................................................................. 28
6.1.18. Fremanezumab - AJovy (CAP) - PSUSA/00010758/202009 ................................................................. 28
6.1.19. Gilteritinib - XOSPATA (CAP) - PSUSA/00010832/202009 ................................................................. 28
6.1.20. Ibalmuzumab - TROGARZO (CAP) - PSUSA/00010797/202009 ................................................................. 28
6.1.21. Idebenone - RAXONE (CAP) - PSUSA/00010412/202009 ................................................................. 28
6.1.22. Influenza vaccine (live attenuated, nasal) - FLUENZ TETRA (CAP) - PSUSA/00001742/202008 ................................................................. 29
6.1.23. Isatuximab - SARCLISA (CAP) - PSUSA/00010851/202009 ................................................................. 29
6.1.24. Isavuconazole - CRESEMB (CAP) - PSUSA/00010426/202009 ................................................................. 29
6.1.25. Linaclotide - CONSTELLA (CAP) - PSUSA/00010025/202008 ................................................................. 29
6.1.26. Lorlatinib - LORVIQUA (CAP) - PSUSA/00010760/202009 ................................................................. 29
6.1.27. Mecasermin - INCRELEX (CAP) - PSUSA/00001942/202008 ................................................................. 29
6.1.28. Mepolizumab - NUCALA (CAP) - PSUSA/00010456/202009 ................................................................. 30
6.1.29. Meropenem, vaborbactam - VABOREM (CAP) - PSUSA/00010727/202008 ................................................................. 30
6.1.30. Moroctocog alfa - REFACTO AF (CAP) - PSUSA/00002089/202008 ................................................................. 30
6.3.11. Naldemedine - RIZMOIC (CAP) - PSUSA/00010753/202009
6.3.12. Naloxegol - MOVENTIG (CAP) - PSUSA/00010317/202009
6.3.13. Naltrexone, bupropion - MYSIMBA (CAP) - PSUSA/00010366/202009
6.3.14. Pandemic influenza vaccine (H5N1) (whole virion, vero cell derived, inactivated) - PANDEMIC INFLUENZA VACCINE H5N1 BAXTER (CAP) - PSUSA/00002282/202008
6.3.15. Pembrolizumab - KEYTRUDA (CAP) - PSUSA/00010403/202009
6.3.16. Raltegravir - ISENTRESS (CAP) - PSUSA/00010373/202009
6.3.17. Risankizumab - SKYRIZI (CAP) - PSUSA/00010765/202009
6.3.18. Rivaroxaban - XARELTO (CAP) - PSUSA/00002653/202009
6.3.19. Sebelipase alfa - KANUMA (CAP) - PSUSA/00010422/202008
6.3.20. Sodium zirconium cyclosilicate - LOKELMA (CAP) - PSUSA/00010675/202009
6.3.21. Solintra - SUNOSI (CAP) - PSUSA/00010831/202009
6.3.22. Tasonermin - BEROMUN (CAP); XAGRID (CAP); NAP
6.3.23. Teduglutide - REVESTIVE (CAP) - PSUSA/00009305/202008
6.3.24. Tildrakizumab - ILUMETRI (CAP) - PSUSA/00010720/202009
6.3.25. Tobramycin - VANTOBRA (CAP) - PSUSA/00010370/202009
6.3.26. Trabectedin - YONDELIS (CAP) - PSUSA/00003001/202009
6.3.27. Velmanase alfa - LAMZEDE (CAP) - PSUSA/00010677/202009

6.2. **PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) and nationally authorised products (NAPs)**

6.2.1. Anagrelide - ANAGRELIDE MYLAN (CAP); XAGRID (CAP); NAP - PSUSA/00000208/202009
6.2.2. Glycopyrronium - SIALANAR (CAP); NAP - PSUSA/00010529/202009
6.2.3. Trientine - CUFENCE (CAP); CUPRIOR (CAP); NAP - PSUSA/00010637/202009
6.2.4. Zoledronic acid - ZOLEDRONIC ACID HOSPIRA (CAP); ZOLEDRONIC ACID MEDAC (CAP); ZOMETTA (CAP); NAP - PSUSA/00003149/202008

6.3. **PSUR single assessment (PSUSA) procedures including nationally authorised products (NAPs) only**

6.3.1. Bromazepam (NAP) - PSUSA/00000435/202008
6.3.2. Dalteparin sodium (NAP) - PSUSA/00000922/202008
6.3.3. Dermatophagoides pteronyssinus, dermatophagoides farina (NAP) - PSUSA/00010582/202009
6.3.4. Dexamfetamine (NAP) - PSUSA/00000986/202009
6.3.5. Dextubuprofen (NAP) - PSUSA/00000996/202008
6.3.6. Hexoprenaline sulfate (NAP) - PSUSA/00003170/202008
6.3.7. Metronidazole, neomycin, nystatin (NAP) - PSUSA/00010508/202009
6.3.8. Modafinil (NAP) - PSUSA/00010242/202008
6.3.9. Nifedipine (NAP) - PSUSA/00002156/202008
6.3.10. Oxcarbazepine (NAP) - PSUSA/00002235/202008
6.3.11. Pefloxacin (NAP) - PSUSA/00002322/202008
6.12. Permethrin (NAP) - PSUSA/00002355/202008 ...................................................... 36
6.13. Phenytoin (NAP) - PSUSA/00002392/202008 ........................................................... 37
6.14. Poractant alfa (NAP) - PSUSA/00002478/202008 ....................................................... 37
6.15. Suxamethonium (NAP) - PSUSA/00002834/202008 ................................................. 37
6.4. Follow-up to PSUR/PSUSA procedures ...................................................................... 37
6.4.1. Docetaxel - TAXOTERE (CAP) - EMEA/H/C/000073/LEG 039 .............................. 37
6.4.2. Pregabalin - LYRICA (CAP) - EMEA/H/C/000546/LEG 054 ................................. 37
6.4.3. Pregabalin - PREGABALIN PFIZER (CAP) - EMEA/H/C/003880/LEG 007 .......... 38
6.5. Variation procedure(s) resulting from PSUSA evaluation ........................................... 38
6.5.1. COVID-19 mRNA vaccine (nucleoside-modified) - COMIRNATY (CAP) - EMEA/H/C/005735/II/0016/G ............................................................... 38
6.5.2. Ocrelizumab - OCREVUS (CAP) - EMEA/H/C/004043/II/0024 ............................. 38
6.6. Expedited summary safety reviews ........................................................................... 39
6.6.1. Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (previously COVID-19 VACCINE ASTRAZENECA) (CAP) - EMEA/H/C/005675/LEG 036 .......................... 39

7. Post-authorisation safety studies (PASS) ................................................................. 39
7.1. Protocols of PASS imposed in the marketing authorisation(s) ................................. 39
7.1.1. Cabotegravir - VOCABRIA (CAP); rilpivirine - REKAMBYS (CAP) - EMEA/H/C/PSP/J/0092 ................................................................. 39
7.1.2. Direct acting antivirals (DAAV): Dasabuvir - EXVIERA (CAP); elbasvir, grazoprevir - ZEPATIER (CAP); glecaprevir, pibrentasvir - MAVIRET (CAP); ledipasvir, sofosbuvir - HARVONI (CAP); ombitasvir, peritrevir, ritonavir - VIEKIRAX (CAP); sofosbuvir - SOVALDI (CAP); sofosbuvir, velpatasvir - EPLUSA (CAP); sofosbuvir, velpatasvir, voxilaprevir - VOSEVI (CAP) - EMEA/H/C/PSA/J/0068 ................................................................. 39
7.1.3. Pitolisant - WAKIX (CAP) - EMEA/H/C/PSA/S/0060.1 ............................................. 40
7.1.4. Sotagliflozin - ZYNQUISTA (CAP) - EMEA/H/C/PSP/S/0084.4 ............................... 40
7.2. Protocols of PASS non-imposed in the marketing authorisation(s) ....................... 40
7.2.1. Cabotegravir - VOCABRIA (CAP) - EMEA/H/C/004976/MEA 004 ..................... 40
7.2.2. Cabotegravir - VOCABRIA (CAP) - EMEA/H/C/004976/MEA 005 ..................... 41
7.2.3. Cabotegravir - VOCABRIA (CAP) - EMEA/H/C/004976/MEA 006 ..................... 41
7.2.4. Coronavirus (COVID-19) mRNA vaccine (nucleoside-modified) - COMIRNATY (CAP) - EMEA/H/C/005735/MEA 017 ............................................. 41
7.2.5. Darbepoetin alfa - ARANESP (CAP) - EMEA/H/C/000332/MEA 092.2 .................... 41
7.2.6. Dimethyl fumarate - TECFIDERA (CAP) - EMEA/H/C/002601/MEA 007.2 .................. 42
7.2.7. Fenofibrate, pravastatin sodium - PRAVAFENIX (CAP) - EMEA/H/C/001243/MEA 007.6 .................................................. 42
7.2.8. Inotersen - TEGSEDI (CAP) - EMEA/H/C/004782/MEA 001.5 ................................. 42
7.2.9. Sotagliflozin - ZYNQUISTA (CAP) - EMEA/H/C/004889/MEA 004.3 .................. 42
7.2.10. Tofacitinib - XELJANZ (CAP) - EMEA/H/C/004214/MEA 015.2 ............................. 43
7.3. Results of PASS imposed in the marketing authorisation(s) ...................................... 43
7.3.1. Aprotinin (NAP) - EMEA/H/N/PSR/S/0030 .......................................................... 43
7.3.2. Dexamfetamine (NAP) - EMEA/H/N/PSR/S/0028 ................................................. 43
7.3.3. Dexamfetamine (NAP) - EMEA/H/N/PSR/S/0029 ................................................. 43

7.4. Results of PASS non-imposed in the marketing authorisation(s).......................... 44
  7.4.2. Human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed) - GARDASIL (CAP) - EMEA/H/C/000703/II/0091 ......................................................... 44
  7.4.3. Insulin detemir - LEVEMIR (CAP) - EMEA/H/C/000528/II/0101 ......................................................... 44
  7.4.4. Linacotide - CONSTELLA (CAP) - EMEA/H/C/002490/II/0053 ......................................................... 45
  7.5. Interim results of imposed and non-imposed PASS submitted before the entry into force of the revised variation regulation ......................................................... 45
    7.5.1. Adalimumab - AMGEVITA (CAP) - EMEA/H/C/004212/MEA 001.2 ......................................................... 45
    7.5.2. Deferasirox - EXJADE (CAP) - EMEA/H/C/000670/ANX 038.12 ......................................................... 45
    7.5.3. Fenofibrate, pravastatin sodium - PRAVAFENIX (CAP) - EMEA/H/C/001243/MEA 007.7 ........ 46
    7.5.4. Golimumab - SIMPONI (CAP) - EMEA/H/C/000992/MEA 033.5 ......................................................... 46
    7.5.5. Infliximab - REMICADE (CAP) - EMEA/H/C/000240/MEA 114.11 ......................................................... 46
  7.6. Others .................................................................................................................................................. 46
    7.6.1. Acalabrutinib - CALQUENCE (CAP) - EMEA/H/C/005299/MEA 002 ......................................................... 46
    7.6.2. Melatonin - SLENYTO (CAP) - EMEA/H/C/004425/REC 002.1 ......................................................... 47
  7.7. New Scientific Advice .......................................................................................................................... 47
  7.8. Ongoing Scientific Advice ................................................................................................................ 47
  7.9. Final Scientific Advice (Reports and Scientific Advice letters) ......................................................... 47

8. Renewals of the marketing authorisation, conditional renewal and annual reassessments 47

  8.1. Annual reassessments of the marketing authorisation ................................................................. 47
  8.2. Conditional renewals of the marketing authorisation .................................................................. 47
    8.2.1. Ataluren - TRANSLARNA (CAP) - EMEA/H/C/002720/R/0061 (without RMP) .......... 47
    8.2.2. Belantamab mafodotin - BLENREP (CAP) - EMEA/H/C/004935/R/0003 (without RMP) ........ 47
    8.2.3. Bulevirtide - HEPCLUDEX (CAP) - EMEA/H/C/004854/R/0003 (without RMP) .......... 48
    8.2.4. Entrectinib - ROZLYTREK (CAP) - EMEA/H/C/004936/R/0002 (without RMP) .......... 48
    8.2.5. Imlifidase - IDEFIRIX (CAP) - EMEA/H/C/004849/R/0003 (without RMP) .......... 48
    8.2.6. Pretomanid - DOVPRELA (CAP) - EMEA/H/C/005167/R/0005 (without RMP) .......... 48
  8.3. Renewals of the marketing authorisation ....................................................................................... 48
    8.3.1. Bortezomib - BORTEZOMIB SUN (CAP) - EMEA/H/C/004076/R/0015 (without RMP) ........ 48
    8.3.2. Enoxaparin sodium - INHIXA (CAP) - EMEA/H/C/004264/R/0076 (with RMP) .......... 49
    8.3.3. Glycopyrronium - SIALANAR (CAP) - EMEA/H/C/003883/R/0018 (without RMP) .......... 49
    8.3.4. Lenvatinib - KISPLYX (CAP) - EMEA/H/C/004224/R/0043 (without RMP) .......... 49
    8.3.5. Methotrexate - NORDIMET (CAP) - EMEA/H/C/003983/R/0018 (without RMP) .......... 49
    8.3.6. Sildenafil - MYSILDECARD (CAP) - EMEA/H/C/004186/R/0009 (without RMP) .......... 49
    8.3.7. Vismodegib - ERIVEDGE (CAP) - EMEA/H/C/002602/R/0050 (without RMP) .......... 49
9. Product related pharmacovigilance inspections ................................................................. 50
9.1. List of planned pharmacovigilance inspections .............................................................. 50
9.2. Ongoing or concluded pharmacovigilance inspections .................................................... 50
9.3. Others ............................................................................................................................... 50

10. Other safety issues for discussion requested by the CHMP or the EMA ........................................ 50
10.1. Safety related variations of the marketing authorisation ................................................ 50
10.2. Timing and message content in relation to Member States’ safety announcements ............ 50
10.3. Other requests .................................................................................................................. 50
10.4. Scientific Advice ............................................................................................................. 50

11. Other safety issues for discussion requested by the Member States ........................................ 51
11.1. Safety related variations of the marketing authorisation ................................................ 51
11.2. Other requests .................................................................................................................. 51
11.2.1. Dinoprostone (NAP) - SE/H/PSUFU/00001104/201909 ................................................ 51
11.2.2. Phenobarbital (NAP) - EE/H/PSUFU/00002370/202001 ................................................. 51

12. Organisational, regulatory and methodological matters ......................................................... 52
12.1. Mandate and organisation of the PRAC .......................................................................... 52
12.1.1. PRAC working group - Best practice guide on using PRAC plenary time efficiently and effectively - update on the implementation of quantitative goals - Q1 2021 ............................... 52
12.2. Coordination with EMA Scientific Committees or CMDh-v ........................................... 52
12.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups ....................... 52
12.4. Cooperation within the EU regulatory network ............................................................... 52
12.4.1. Coronavirus (COVID-19) pandemic - update ............................................................... 52
12.4.2. Heads of Medicines Agencies (HMA)-EMA joint big data - Big data steering group: data standards strategy initiative - call for expressions of interest ..................................................... 52
12.4.3. Joint advisory board (JAB) for COVID-19 vaccines studies - call for expressions of interest 52
12.4.4. PRAC strategic review and learning meeting (SRLM) under the Portuguese presidency of the European Union (EU) Council - Remote meeting, 23 April 2021 - agenda ......................................... 52
12.5. Cooperation with International Regulators ...................................................................... 52
12.6. Contacts of the PRAC with external parties and interaction with the Interested Parties to the Committee ....................................................................................................................... 53
12.7. PRAC work plan .............................................................................................................. 53
12.8. Planning and reporting .................................................................................................... 53
12.8.1. Marketing authorisation applications (MAA) forecast for 2021 - planning update dated Q1 2021 .................................................................................................................................................. 53
12.8.2. PRAC workload statistics - Q1 2021 ........................................................................... 53
12.9. Pharmacovigilance audits and inspections .................................................................... 53
12.9.1. Pharmacovigilance systems and their quality systems .................................................. 53
12.9.2. Pharmacovigilance inspections .................................................................................... 53
12.9.3. Pharmacovigilance audits .............................................................................................................. 53
12.10. Periodic safety update reports (PSURs) & Union reference date (EURD) list ............ 53
12.10.1. Periodic safety update reports ........................................................................................................ 53
12.10.2. Granularity and Periodicity Advisory Group (GPAG) ................................................................. 53
12.10.3. PSURs repository ............................................................................................................................. 54
12.10.4. Union reference date list - consultation on the draft list .......................................................... 54
12.11. Signal management ......................................................................................................................... 54
12.12. Adverse drug reactions reporting and additional reporting ............................................... 54
12.12.1. Management and reporting of adverse reactions to medicinal products ................................. 54
12.12.2. Additional monitoring ....................................................................................................................... 54
12.12.3. List of products under additional monitoring - consultation on the draft list ....................... 54
12.13. EudraVigilance database ................................................................................................................. 54
12.13.1. Activities related to the confirmation of full functionality ............................................................... 54
12.14. Risk management plans and effectiveness of risk minimisations ........................................... 54
12.14.1. Risk management systems .............................................................................................................. 54
12.15. Post-authorisation safety studies (PASS) ...................................................................................... 55
12.15.1. Post-authorisation Safety Studies - imposed PASS ...................................................................... 55
12.15.2. Post-authorisation Safety Studies - non-imposed PASS .............................................................. 55
12.16. Community procedures .................................................................................................................. 55
12.16.1. Referral procedures for safety reasons ............................................................................................ 55
12.17. Renewals, conditional renewals, annual reassessments ............................................................. 55
12.18. Risk communication and transparency ......................................................................................... 55
12.18.1. Public participation in pharmacovigilance .................................................................................... 55
12.18.2. Safety communication .................................................................................................................... 55
12.19. Continuous pharmacovigilance ....................................................................................................... 55
12.19.1. Incident management ...................................................................................................................... 55
12.20. Others ................................................................................................................................................... 56
12.20.1. Real world data (RWE) use in marketing authorisation applications and extensions of indications - EMA study preliminary results .................................................................................. 56
12.20.2. Video conferencing tool - WebEx rollout plan for PRAC ............................................................ 56

13. Any other business ................................................................................................................................. 56
14. Explanatory notes .................................................................................................................................. 57
1. **Introduction**

1.1. **Welcome and declarations of interest of members, alternates and experts**

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the PRAC plenary session to be held 06-09 April 2021. See April 2021 PRAC minutes (to be published post May 2021 PRAC meeting).

1.2. **Agenda of the meeting on 06-09 April 2021**

**Action:** For adoption

1.3. **Minutes of the previous meeting on 08-11 March 2021**

**Action:** For adoption

2. **EU referral procedures for safety reasons: urgent EU procedures**

2.1. **Newly triggered procedures**

None

2.2. **Ongoing procedures**

None

2.3. **Procedures for finalisation**

None

3. **EU referral procedures for safety reasons: other EU referral procedures**

3.1. **Newly triggered procedures**

None

3.2. **Ongoing procedures**

None
3.3. **Procedures for finalisation**

None

3.4. **Re-examination procedures**

None

3.5. **Others**

None

4. **Signals assessment and prioritisation**

4.1. **New signals detected from EU spontaneous reporting systems**

4.1.1. **Coronavirus (COVID-19) vaccine (Ad26.COV2-S [recombinant]) - COVID-19 vaccine JANSSEN (CAP)**

Applicant(s): Janssen-Cilag International NV
PRAC Rapporteur: Ulla Wändel Liminga
Scope: Signal of embolic and thrombotic events
**Action:** For adoption of PRAC recommendation
EPITT 19689 – New signal
Lead Member State(s): SE

4.1.2. **Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (previously COVID-19 VACCINE ASTRAZENECA) (CAP)**

Applicant(s): AstraZeneca AB
PRAC Rapporteur: Jean-Michel Dogné
Scope: Signal of capillary leak syndrome
**Action:** For adoption of PRAC recommendation
EPITT 19672 – New signal
Lead Member State(s): BE

4.1.3. **Fluoroquinolones:**
ciprofloxacin (NAP); delafloxacin - QUOFENIX (CAP); levofloxacin – QUINSAIR

---

1 Re-examination of PRAC recommendation under Article 32 of Directive 2001/83/EC
2 Each signal refers to a substance or therapeutic class. The route of marketing authorisation is indicated in brackets (CAP for Centrally Authorised Products; NAP for Nationally Authorised Products including products authorised via Mutual Recognition Procedures and Decentralised Procedure). Product names are listed for reference Centrally Authorised Products (CAP) only. PRAC recommendations will specify the products concerned in case of any regulatory action required.
Applicant(s): A. Menarini Industrie Farmaceutiche Riunite s.r.l. (Quofenix), Chiesi Farmaceutici S.p.A. (Quinsair), various
PRAC Rapporteur: To be appointed
Scope: Signal of acquired thrombotic thrombocytopenia purpura
Action: For adoption of PRAC recommendation
EPITT 19669 – New signal
Lead Member State(s): DE, ES, HR, IT, NO, SI

4.1.4. Pembrolizumab – KEYTRUDA (CAP)

Applicant(s): Merck Sharp & Dohme B.V.
PRAC Rapporteur: Menno van der Elst
Scope: Signal of paraneoplastic neurological syndrome
Action: For adoption of PRAC recommendation
EPITT 19671 – New signal
Lead Member State(s): NL

4.1.5. Piperacillin (NAP); piperacillin, tazobactam (NAP)

Applicant(s): various
PRAC Rapporteur: To be appointed
Scope: Signal of hemophagocytic lymphohistiocytosis (HLH)
Action: For adoption of PRAC recommendation
EPITT 19676 – New signal
Lead Member State(s): IT, SK

4.2. New signals detected from other sources

None

4.3. Signals follow-up and prioritisation

4.3.1. Azathioprine (NAP)

Applicant(s): various
PRAC Rapporteur: Anette Kristine Stark
Scope: Signal of erythema nodosum
4.3.2. **Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (previously COVID-19 VACCINE ASTRazeneca) (CAP) - EMEA/H/C/005675/SDA/035**

Applicant(s): AstraZeneca AB  
PRAC Rapporteur: Jean-Michel Dogné  
Scope: Signal of embolic and thrombotic events  
**Action:** For adoption of PRAC recommendation  
EPITT 19683 – Follow-up to March 2021

4.4. **Variation procedure(s) resulting from signal evaluation**

None

5. **Risk management plans (RMPs)**

5.1. **Medicines in the pre-authorisation phase**

5.1.1. **Bimekizumab - EMEA/H/C/005316**

Scope: Treatment of plaque psoriasis  
**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.2. **Eladocagene exuparvovec - EMEA/H/C/005352, Orphan**

Applicant: PTC Therapeutics International Limited, ATMP\(^3\)  
Scope: Treatment of aromatic L-amino acid decarboxylase (AADC) deficiency  
**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CAT and CHMP

5.1.3. **Imatinib - EMEA/H/C/005595**

Scope: Treatment of Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML), Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL), myelodysplastic/myeloproliferative diseases (MDS/MPD), hypereosinophilic syndrome (HES), eosinophilic leukaemia (CEL), Kit (CD 117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST) and unresectable dermatofibrosarcoma protuberans (DFSP)

\(^3\) Advanced therapy medicinal product
**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.4. **Lisocabtagene maraleucel - EMEA/H/C/004731, Orphan**

Applicant: Bristol-Myers Squibb Pharma EEIG, ATMP

Scope: Treatment of large B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B)

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CAT and CHMP

5.1.5. **Vosoritide - EMEA/H/C/005475, Orphan**

Applicant: BioMarin International Limited

Scope: Treatment of achondroplasia

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.6. **Zanubrutinib - EMEA/H/C/004978, Orphan**

Applicant: BeiGene Ireland Ltd

Scope: Treatment of Waldenström’s macroglobulinaemia (WM)

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.2. **Medicines in the post-authorisation phase – PRAC-led procedures**

5.2.1. **Cetrorelix - CETROTIDE (CAP) - EMEA/H/C/000233/II/0075**

Applicant: Merck Europe B.V.

PRAC Rapporteur: Martin Huber

Scope: Submission of an updated RMP (version 5.2) in order to bring it in line with revision 2 of GVP module V on ‘Risk management systems’ including the consequential removal of a number of important identified risks and important potential risk of congenital anomalies, as well as the removal of missing information on infertile premenopausal women. The MAH also revised the RMP based on the most recent data and post-marketing exposure

**Action:** For adoption of PRAC Assessment Report

5.2.2. **Elosulfase alfa - VIMIZIM (CAP) - EMEA/H/C/002779/II/0034, Orphan**

Applicant: BioMarin International Limited

PRAC Rapporteur: Rhea Fitzgerald

Scope: Submission of an updated RMP (version 5.0) in order to update the safety

---

4 Advanced therapy medicinal product
specifications and the pharmacovigilance plan, and to add healthcare provider educational materials and process indicator to evaluate the distribution of the educational materials. The RMP is also brought in line with revision 2.0.1 of the guidance on the format of RMP in the EU (template)

**Action:** For adoption of PRAC Assessment Report

### 5.2.3. Ibritumomab tiuxetan - ZEVALIN (CAP) - EMEA/H/C/000547/II/0053

**Applicant:** Cefit Biopharma s.r.o.

**PRAC Rapporteur:** Anette Kirstine Stark

**Scope:** Submission of an updated RMP (version 5.0) in line with revision 2 of GVP module V on ‘Risk management systems’

**Action:** For adoption of PRAC Assessment Report

### 5.2.4. Neratinib - NERLYNX (CAP) - EMEA/H/C/004030/II/0020

**Applicant:** Pierre Fabre Medicament

**PRAC Rapporteur:** Menno van der Elst

**Scope:** Submission of an updated RMP (version 1.1) in order to amend the list of important identified risks, to update data concerning PASS studies and to change the submission due date of the final results of study PUMA-NER-6201 (MEA 001): an open-label study to characterize the incidence and severity of diarrhoea in patients with early stage human epidermal growth factor receptor 2 positive (HER2+) breast cancer treated with neratinib and intensive loperamide prophylaxis, with/without anti-inflammatory treatment (budesonide) and with/without a bile acid sequestrant (colestipol), from Q1 2021 to Q4 2021

**Action:** For adoption of PRAC Assessment Report

### 5.2.5. Rasagiline - AZILECT (CAP) - EMEA/H/C/000574/WS2011/0087; RASAGILINE RATIOPHARM (CAP) - EMEA/H/C/003957/WS2011/0019

**Applicant:** Teva B.V.

**PRAC Rapporteur:** Ana Sofia Diniz Martins

**Scope:** Submission of an updated RMP (version 3.0) following the completion of study TV1030-CNS-50024 (listed as a category 3 study in the RMP): a non-interventional retrospective cohort study which was conducted using the United States Medicare research database to assess the potential risk of melanoma associated with the use of rasagiline mesylate in patients with Parkinson's disease (as assessed and concluded in procedure WS/1749 finalised in September 2020). The MAH took the opportunity to introduce a minor update to the targeted follow-up questionnaire for the important potential risk of malignant melanoma and to revise the list of safety concerns in line with revision 2.0.1 of the guidance on the format of RMP in the EU (template)

**Action:** For adoption of PRAC Assessment Report
5.2.6. **Tolvaptan - JINARC (CAP) - EMEA/H/C/002788/II/0029**

Applicant: Otsuka Pharmaceutical Netherlands B.V.

PRAC Rapporteur: Amelia Cupelli

Scope: Submission of an updated RMP (version 14.4) to include dehydration and the pregnancy prevention programme as additional risk minimisation measures (aRMM) in order to align the RMP with Annex II-D on ‘Conditions or restrictions with regard to the safe and effective use of the medicinal product’

Action: For adoption of PRAC Assessment Report

5.3. **Medicines in the post-authorisation phase – CHMP-led procedures**

5.3.1. **Alpelisib - PIQRAY (CAP) - EMEA/H/C/004804/II/0005/G**

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Menno van der Elst

Scope: Grouped variations consisting of: 1) update of sections 4.4 and 4.8 of the SmPC in order to add hyperglycaemic hyperosmolar non-ketotic syndrome to the list of adverse drug reactions (ADRs) with frequency ‘unknown’ and to update the warning on hyperglycaemia and ketoacidosis based on a review of the safety database. The package leaflet and Annex II are updated accordingly. The RMP (version 3.0) is updated accordingly; 2) update of sections 4.2 and 4.8 of the SmPC to modify the management of hyperglycaemia, rash and diarrhoea and add information about osteonecrosis of the jaw based on pivotal trial SOLAR-1: a phase 3 randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment. The MAH also took the opportunity to make minor editorial changes to the SmPC

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.2. **Axicabtagene ciloleucel - YESCARTA (CAP) - EMEA/H/C/004480/II/0028, Orphan**

Applicant: Kite Pharma EU B.V., ATMP

PRAC Rapporteur: Anette Kirstine Stark

Scope: Update of sections 4.4, 4.8 and 5.1 of the SmPC to update the safety information based on updates from study KTE-C19-101: a phase 1/2 multicentre study evaluating the safety and efficacy of Yescarta (axicabtagene ciloleucel (KTE-C19)) in subjects with refractory aggressive non-Hodgkin lymphoma (ZUMA-1). The updates include data from: 1) phase 2 safety management ZUMA-1 cohort 4 intended to assess the impact of earlier interventions on the rate and severity of cytokine release syndrome (CRS) and neurologic events; 2) a 36-month analysis from ZUMA-1 cohorts 1 and 2. The RMP (version 3.1) is updated accordingly

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CAT

---

5 Advanced therapy medicinal product
5.3.3. Belatacept - NULOJIX (CAP) - EMEA/H/C/002098/II/0070

Applicant: Bristol-Myers Squibb Pharma EEIG
PRAC Rapporteur: Ulla Wändel Liminga

Scope: Extension of indication to include the use of belatacept in conversion from a calcineurin inhibitor-based regimen to a belatacept-based regimen post transplantation. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The package leaflet and the RMP (version 18.0) are updated in accordance. Furthermore, the MAH took the opportunity to bring the product information in line with the latest quality review of documents (QRD) template (version 10.1) and to update it with regard to sodium content in line with the Annex to the European Commission (EC) guideline on 'excipients in the labelling and package leaflet of medicinal products for human use'.

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.4. Budesonide, formoterol - BIRESP SPIROMAX (CAP) - EMEA/H/C/003890/II/0033/G

Applicant: Teva Pharma B.V.
PRAC Rapporteur: Anette Kirstine Stark

Scope: Grouped variation consisting of: 1) extension of indication to include adolescents of 12 years and older for the regular treatment of asthma, where the use in combination of an inhaled corticosteroid and long-acting β2 adrenoceptor agonist is appropriate, either in patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β2 adrenoceptor agonists, or in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists. The extension to the indication is based upon data from the literature. As a consequence, sections 4.1, 4.2, 5.1 and 5.2 of the SmPC are updated. The package leaflet and the RMP (version 3.0) are updated accordingly. In addition, the MAH took the opportunity to make an administrative update to the Greek, Icelandic, Irish and Maltese local representatives. Furthermore, the product information is brought in line with the latest quality review of documents (QRD) template (version 10.1); 2) update of sections 4.2, 5.1 and 5.2 of the SmPC to update the information on paediatric data and section 4.4 of the SmPC to remove the warning regarding the risk of growth retardation in children and the guidance on how to address this risk as agreed during the assessment of the initial application for Budesonide/Formoterol Teva Pharma B.V finalised in January 2020

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.5. Budesonide, formoterol - DUORESP SPIROMAX (CAP) - EMEA/H/C/002348/II/0033/G

Applicant: Teva Pharma B.V.
PRAC Rapporteur: Anette Kirstine Stark

Scope: Grouped variation consisting of: 1) extension of indication to include adolescents of 12 years and older for the regular treatment of asthma, where the use in combination of an
inhaled corticosteroid and long-acting β2 adrenoceptor agonist is appropriate, either in patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β2 adrenoceptor agonists, or in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists. The extension to the indication is based upon data from the literature. As a consequence, sections 4.1, 4.2, 5.1 and 5.2 of the SmPC are updated. The package leaflet and the RMP (version 3.0) are updated accordingly. In addition, the MAH took the opportunity to make an administrative update to the Greek, Icelandic, Irish and Maltese local representatives. Furthermore, the product information is brought in line with the latest quality review of documents (QRD) template (version 10.1); 2) update of sections 4.2, 5.1 and 5.2 of the SmPC to update the information on paediatric data and section 4.4 of the SmPC to remove the warning regarding the risk of growth retardation in children and the guidance on how to address this risk as agreed during the assessment of the initial application for Budesonide/Formoterol Teva Pharma B.V finalised in January 2020.

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.6. Burosumab - CRYSVITA (CAP) - EMEA/H/C/004275/II/0023, Orphan

**Applicant:** Kyowa Kirin Holdings B.V.

**PRAC Rapporteur:** Brigitte Keller-Stanislawski

**Scope:** Extension of indication to include treatment of fibroblast growth factor 23 (FGF23)-related hypophosphataemia in tumour-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in patients aged 1 year and over, based on data from two ongoing open-label clinical studies, namely: 1) study UX023T-CL201: a phase 2 open-label trial to assess the efficacy and safety of burosumab in subjects with TIO or epidermal nevus syndrome (ENS)-associated osteomalacia, 2) study KRN23-002: a phase 2 Open-label trial to assess the efficacy and safety of burosumab in patients with TIO or ENS (144-week data and 88-week data respectively). As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet and the RMP (version 4.0) are updated accordingly. The MAH also applied for one additional year of market protection.

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.7. Clopidogrel - ISCOVER (CAP) - EMEA/H/C/000175/WS1820/0142; PLAVIX (CAP) - EMEA/H/C/000174/WS1820/0140

**Applicant:** Sanofi-aventis groupe

**PRAC Rapporteur:** Marcia Sofia Sanches de Castro Lopes Silva

**Scope:** Update of section 4.2 of the SmPC in order to add 600 mg as an alternative loading dose to the existing 300 mg to be used at initiation of treatment in the indication of secondary prevention of atherothrombotic events in adult patients suffering from acute coronary syndrome. This update is based on a bibliographic review of published studies. The package leaflet and the RMP (version 2.0) are updated accordingly.

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP
5.3.8. **Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) – VAXZEVRIA (previously COVID-19 VACCINE ASTRAZENECA) (CAP) - EMEA/H/C/005675/II/0002**

Applicant: AstraZeneca AB

PRAC Rapporteur: Jean-Michel Dogné

Scope: Update of section 4.8 of the SmPC in order to update the safety profile and to add the adverse drug reactions: abdominal pain and urticaria with frequency uncommon and pain in extremity and influenza-line illness with frequency common based on the primary analysis from the pooled pivotal studies (listed as a specific obligation in the Annex II) namely: 1) study COV001: a phase 1/2 study to determine efficacy, safety and immunogenicity of the candidate coronavirus disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers; 2) study COV002: a single-blind, randomised, controlled, phase 2/3 trial assessing the safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults conducted in the UK; 3) study COV003: a single-blinded, multicentre, randomised, controlled phase 3 trial assessing the safety, efficacy, and immunogenicity of AZD1222 in participants in Brazil; 4) study COV005: a blinded, multicentre, randomised, controlled phase 1/2 trial assessing the safety, efficacy, and immunogenicity of AZD1222 in participants in South Africa. The MAH took the opportunity to introduce some editorial changes throughout the product information. The package leaflet, labelling and the RMP (version 2.1) are updated accordingly

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.9. **COVID-19 mRNA⁶ vaccine (nucleoside-modified) - COMIRNATY (CAP) - EMEA/H/C/005735/II/0019**

Applicant: BioNTech Manufacturing GmbH

PRAC Rapporteur: Menno van der Elst

Scope: Proposal to replace post-authorisation effectiveness epidemiology study C4591014 currently included in the RMP (listed as a category 3 study in the RMP): a test-negative design to evaluate the effectiveness of Comirnaty (BNT162b2 – COVID-19 vaccine) against acute respiratory illness due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults ≥18 years of age as a milestone with three other studies to pursue the same objective. The RMP (version 1.1) is updated accordingly

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.10. **Dapagliflozin - EDISTRIDE (CAP) - EMEA/H/C/004161/WS1952/0042; FORXIGA (CAP) - EMEA/H/C/002322/WS1952/0060**

Applicant: AstraZeneca AB

PRAC Rapporteur: Annika Folin

Scope: Extension of indication for Forxiga and Edistride (dapagliflozin) to include treatment of children aged 10 years and adolescents with type 2 diabetes mellitus (T2DM) based on the results from studies: 1) study MB10209/D1690C000016: a randomised, multicentre, parallel, single-dose study to explore the pharmacokinetics and pharmacodynamics of

⁶ Messenger ribonucleic acid
dapagliflozin in children, 10 to less than 18 years of age with T2DM receiving one of three dose levels of dapagliflozin: 2.5, 5 or 10 mg; 2) study MB102-138/D1690C00017: a randomised, double-blind, placebo-controlled, 24 week efficacy and safety study of dapagliflozin 10 mg as compared to placebo with a 28-week open label safety extension phase, in patients aged from 10 to less than 18 years (and young adults from 18 to less than 25 years) with T2DM who have inadequate glycaemic control on diet and exercise with: either metformin only, or insulin only or with metformin and insulin. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet and the RMP (version 21.0) are updated in accordance.

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.11. Empagliflozin - JARDIANCCE (CAP) - EMEA/H/C/002677/II/0055

**Applicant:** Boehringer Ingelheim International GmbH

**PRAC Rapporteur:** Eva Segovia

**Scope:** Extension of indication to include treatment of adult patients with heart failure and reduced ejection fraction. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 4.9 and 5.1 of the SmPC are updated based on final results from study EMPEROR-Reduced: a phase 3 randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo in patients with chronic heart failure with reduced ejection fraction (HFrEF). The package leaflet, labelling and the RMP (version 15.0) are updated in accordance. In addition, the MAH took the opportunity to update the list of local representatives in the package leaflet.

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.12. Erenumab - AIMOVIG (CAP) - EMEA/H/C/004447/II/0013/G

**Applicant:** Novartis Europharm Limited

**PRAC Rapporteur:** Kirsti Villikka

**Scope:** Grouped variations consisting of: 1) update of section 4.8 of the SmPC to add alopecia, oral sores and rash in line with revised clinical safety data; 2) update of sections 4.8 and 5.1 of the SmPC based on the study report from 5-year open-label study 20120178: a phase 2, multicentre, randomized, double-blind, placebo-controlled, parallel-group study of subjects with episodic migraine; 3) update of section 5.1 of the SmPC to include of the anatomical therapeutic chemical (ATC) classification system code for erenumab. The package leaflet and the RMP (version 3.0) are updated accordingly.

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.13. Filgotinib - JYSELECA (CAP) - EMEA/H/C/005113/II/0003

**Applicant:** Gilead Sciences Ireland UC

**PRAC Rapporteur:** Nikica Mirošević Skvrce

**Scope:** Update of sections 4.5 and 5.2 of the SmPC to update the wording on the inhibition of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) by the primary metabolite of filgotinib (GS-829845) based upon results from an in vitro study AD-417-2028.
which assessed in vitro inhibition of human P-gp and BCRP by filgotinib. The package leaflet and the RMP (version 1.2) are updated accordingly

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.14. Filgrastim - ACCOFIL (CAP) - EMEA/H/C/003956/II/0046/G

**Applicant:** Accord Healthcare S.L.U.

**PRAC Rapporteur:** Kirsti Villikka

**Scope:** Grouped variations consisting of: 1) introduction of a new presentation Accofil 12 MU/0.2 mL solution for injection or infusion in pre-filled syringe; 2) introduction of a new presentation, Accofil 70 MU/0.73 mL solution for injection or infusion in pre-filled syringe. The product information and the RMP (version 5) are updated accordingly

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.15. Lomitapide - LOJUXTA (CAP) - EMEA/H/C/002578/II/0046

**Applicant:** Amryt Pharmaceuticals DAC

**PRAC Rapporteur:** Menno van der Elst

**Scope:** Submission of an alternative study: an evaluation of the effect of lomitapide treatment on major adverse cardiovascular events (MACE) in patients with homozygous familial hypercholesterolemia (LILITH) to the currently agreed protocol for study on the effects of lomitapide on carotid and aortic atherosclerosis in patients treated with lomitapide in usual care (CAPTURE) in order to propose an evaluation of the effect of lomitapide treatment on MACE in patients with homozygous familial hypercholesterolemia. As a consequence, Annex II-D on 'Conditions or restrictions with regard to the safe and effective use of the medicinal product' and the RMP (version 6.4) are updated accordingly. In addition, the MAH took the opportunity to bring the product information in line with the latest quality review of documents (QRD) template (version 10.2)

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.16. Paliperidone - PALIPERIDONE JANSSEN-CILAG INTERNATIONAL (CAP) - EMEA/H/C/005486/X/0002/G

**Applicant:** Janssen-Cilag International N.V.

**PRAC Rapporteur:** Ulla Wändel Liminga

**Scope:** Grouped applications consisting of: 1) extension application to introduce two new strengths of 700 mg and 1000 mg prolonged-release suspension for injection. The RMP (version 10.1) is updated accordingly; 2) change of the (invented) name of the medicinal product from Paliperidone Janssen-Cilag International to Byannli; 3) deletion of the 25 mg, 50 mg, 75 mg, 100 mg and 150 mg/100 mg strengths from the Paliperidone Janssen-Cilag marketing authorisation (EU/1/20/1453/001-006)

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP
5.3.17. Pertuzumab - PERJETA (CAP) - EMEA/H/C/002547/II/0054

Applicant: Roche Registration GmbH
PRAC Rapporteur: Anette Kirstine Stark

Scope: Submission of the final report from study MO28047 (PERUSE) (listed as an obligation in Annex II): a multicentre, open-label, single-arm study of pertuzumab in combination with trastuzumab and taxane in first line treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive advanced (metastatic or locally recurrent) breast cancer. The RMP (version 13.0) is updated accordingly

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.18. Pirfenidone - ESBRIET (CAP) - EMEA/H/C/002154/II/0069

Applicant: Roche Registration GmbH
PRAC Rapporteur: Rhea Fitzgerald

Scope: Extension of indication to include the treatment of unclassifiable interstitial lung disease (UILD). As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The package leaflet and the RMP (version 11.0) are updated in accordance

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.19. Pitolisant - WAKIX (CAP) - EMEA/H/C/002616/II/0023/G, Orphan

Applicant: Bioprojet Pharma
PRAC Rapporteur: Kirsti Villikka

Scope: Grouped variations consisting of an update of sections 4.2, 4.4, 4.5, 5.1 and 5.2 of the SmPC based on new clinical data from: 1) study P09-10 (HARMONY III): an open-label naturalistic pragmatic study to assess the long-term safety of pitolisant in the treatment of excessive daytime sleepiness (EDS) (with or without cataplexy) in narcolepsy; 2) study P16-02: a randomised, double-blind, active- and placebo-controlled, single-dummy, 4-way crossover study to determine the abuse potential of pitolisant compared to phentermine and placebo, in healthy, non-dependent recreational stimulant users. The proposed update also includes results of a post approval network meta-analysis which compares efficacy and safety of multiple treatments, multi-arm studies, and multi-criteria treatment decisions. The package leaflet and the RMP (version 6.0) are updated accordingly

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.20. Raltegravir - ISENTRESS (CAP) - EMEA/H/C/000860/II/0093

Applicant: Merck Sharp & Dohme B.V.
PRAC Rapporteur: Adrien Inoubli

Scope: Update of section 4.6 of the SmPC in order to update safety information following pregnancy outcome data for raltegravir 400 mg film-coated tablet from prospective reports of pregnancy data with known outcome and time of raltegravir exposure. The RMP (version 15.1) is updated accordingly. In addition, the MAH took the opportunity to introduce some
minor changes agreed in previous procedures in the product information and to update the list of local representatives for Germany. Finally, the product information is brought in line with the latest quality review of documents (QRD) template (version 10.1)

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.21.  **Ravulizumab - ULTOMIRIS (CAP) - EMEA/H/C/004954/II/0010**

Applicant: Alexion Europe SAS
PRAC Rapporteur: Kimmo Jaakkola
Scope: Extension of indication to include treatment of paediatric patients with paroxysmal nocturnal haemoglobinuria (PNH). As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, and 5.2 of the SmPC are updated. The package leaflet and the RMP (version 2.1) are updated in accordance. In addition, Annex II is updated to reflect the addition of a PNH parent guide

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.22.  **Rurioctocog alfa pegol - ADYNOVI (CAP) - EMEA/H/C/004195/X/0018**

Applicant: Baxalta Innovations GmbH
PRAC Rapporteur: Menno van der Elst
Scope: Extension application to add a new strength of 3000 IU for rurioctocog alfa pegol powder and solvent for solution for injection, for intravenous use. The RMP (version 2.1) is updated in accordance. Furthermore, the MAH took opportunity to include editorial changes throughout the product information

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.23.  **Sodium phenylbutyrate - PHEBURANE (CAP) - EMEA/H/C/002500/X/0026**

Applicant: Eurocept International B.V.
PRAC Rapporteur: Rhea Fitzgerald
Scope: Extension application to introduce a new pharmaceutical form associated with a new strength (350 mg/mL oral solution). The RMP (version 0.1) is updated in accordance

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.24.  **Sodium phenylbutyrate - PHEBURANE (CAP) - EMEA/H/C/002500/X/0028**

Applicant: Eurocept International B.V.
PRAC Rapporteur: Rhea Fitzgerald
Scope: Extension application to introduce a new pharmaceutical form associated with a new strength (500 mg film-coated tablets). The RMP (version 0.1) is updated in accordance

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP
5.3.25. Tenofvir alafenamide - VEMLIDY (CAP) - EMEA/H/C/004169/II/0030

Applicant: Gilead Sciences Ireland UC
PRAC Rapporteur: Ilaria Baldelli
Scope: Submission of the final report from study GS-US-320-4018 (listed as a category 3 study in the RMP): a phase 3, randomized, double blind study to evaluate the efficacy and safety of switching from tenofovir disoproxil fumarate 300 mg once daily to tenofovir alafenamide 25 mg once daily in subjects with chronic hepatitis B who are virologically suppressed. The RMP (version 6.1) is updated accordingly

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.26. Teriflunomide - AUBAGIO (CAP) - EMEA/H/C/002514/X/0031/G

Applicant: Sanofi-aventis groupe
PRAC Rapporteur: Martin Huber
Scope: Grouped application consisting of: 1) extension application to add a new strength of 7 mg film-coated tablet for use in paediatric patients from 10 years of age and older with relapsing remitting multiple sclerosis (MS); 2) extension of indication to include treatment of paediatric patients aged 10 years and older with relapsing remitting MS for Aubagio (teriflunomide) 14 mg tablet. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The package leaflet, labelling and the RMP (version 6.0) are updated in accordance. The MAH also applied for an extension of the market protection of one additional year in line with the guidance on elements required to support significant clinical benefit in comparison with existing therapies of a new therapeutic indication

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.27. Venetoclax - VENCLYXTO (CAP) - EMEA/H/C/004106/II/0030

Applicant: AbbVie Deutschland GmbH & Co. KG
PRAC Rapporteur: Eva Jirsová
Scope: Extension of indication in combination with hypomethylating agents (HMAs) or low dose cytarabine (LDAC) for the treatment of adult patients with newly-diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. As a consequence, sections 4.2, 4.3, 4.4, 4.5, 4.7, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet and RMP (version 6.1) are updated accordingly

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP
6. Periodic safety update reports (PSURs)

6.1. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) only

6.1.1. Alemtuzumab - LEMTRADA (CAP) - PSUSA/00010055/202009 (with RMP)

Applicant: Sanofi Belgium
PRAC Rapporteur: Anette Kirstine Stark
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.2. Avelumab - BAVENCIO (CAP) - PSUSA/00010635/202009

Applicant: Merck Europe B.V.
PRAC Rapporteur: Anette Kirstine Stark
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.3. Azilsartan medoxomil - EDARBI (CAP) - PSUSA/00000280/202008

Applicant: Takeda Pharma A/S
PRAC Rapporteur: Menno van der Elst
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.4. Bedaquiline - SIRTURO (CAP) - PSUSA/00010074/202009

Applicant: Janssen-Cilag International NV
PRAC Rapporteur: Ulla Wändel Liminga
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.5. Caplacizumab - CABLIVI (CAP) - PSUSA/00010713/202008

Applicant: Ablynx NV
PRAC Rapporteur: Jan Neuhauser
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP
6.1.6. **Cholic acid** - ORPHACOL (CAP) - PSUSA/00010208/202009

Applicant: Laboratoires CTRS  
PRAC Rapporteur: Sofia Trantza  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

6.1.7. **Ciclosporin** - IKERVIS (CAP); VERKAZIA (CAP) - PSUSA/00010362/202009

Applicant(s): Santen Oy  
PRAC Rapporteur: Jan Neuhauser  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

6.1.8. **Damoctocog alfa pegol** - JIVI (CAP) - PSUSA/00010732/202008

Applicant: Bayer AG  
PRAC Rapporteur: Menno van der Elst  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

6.1.9. **Darunavir, cobicistat, emtricitabine, tenofovir alafenamide** - SYMTUZA (CAP) - PSUSA/00010646/202009

Applicant: Janssen-Cilag International N.V.  
PRAC Rapporteur: Ana Sofia Diniz Martins  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

6.1.10. **Darvadstrocel** - ALOFISEL (CAP) - PSUSA/00010676/202009

Applicant: Takeda Pharma A/S, ATMP  
PRAC Rapporteur: Brigitte Keller-Stanislawski  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CAT and CHMP

---

7 Treatment of inborn errors in primary bile acid synthesis due to 3β-hydroxy-Δ5-C27-steroid oxidoreductase deficiency or Δ4-3-oxosteroid-5β-reductase indication(s) only
8 Topical use only
9 Advanced therapy medicinal product
6.1.11. Doravirine - PIFELTRO (CAP) - PSUSA/00010729/202008

Applicant: Merck Sharp & Dohme B.V.
PRAC Rapporteur: Ana Sofia Diniz Martins
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.12. Doravirine, lamivudine, tenofovir disoproxil - DELSTRIGO (CAP) - PSUSA/00010731/202008

Applicant: Merck Sharp & Dohme B.V.
PRAC Rapporteur: Ana Sofia Diniz Martins
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.13. Dulaglutide - TRULICITY (CAP) - PSUSA/00010311/202009

Applicant: Eli Lilly Nederland B.V.
PRAC Rapporteur: Ilaria Baldelli
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.14. Eluxadoline - TRUBERZI\textsuperscript{10} - PSUSA/00010528/202009

Applicant: Allergan Pharmaceuticals International Limited
PRAC Rapporteur: Adam Przybylkowski
Scope: Evaluation of a PSUSA procedure
Action: For discussion

6.1.15. Emtricitabine, rilpivirine, tenofovir disoproxil - EVIPLERA (CAP) - PSUSA/00009142/202008

Applicant: Gilead Sciences Ireland UC
PRAC Rapporteur: Liana Gross-Martirosyan
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.16. Enzalutamide - XTANDI (CAP) - PSUSA/00010095/202008

Applicant: Astellas Pharma Europe B.V.

\textsuperscript{10} European Commission (EC) decision on the marketing authorisation (MA) withdrawal of Truberzi dated 18 December 2020
PRAC Rapporteur: Eva Segovia
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.1.17. **Esketamine**\(^{11}\) - **SPRAVATO (CAP)** - **PSUSA/00010825/202009**

Applicant: Janssen-Cilag International N.V.
PRAC Rapporteur: Kirsti Villikka
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.1.18. **Fremanezumab** - **AJOVY (CAP)** - **PSUSA/00010758/202009**

Applicant: Teva GmbH
PRAC Rapporteur: Kirsti Villikka
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.1.19. **Gilteritinib** - **XOSPATA (CAP)** - **PSUSA/00010832/202009**

Applicant: Astellas Pharma Europe B.V.
PRAC Rapporteur: Martin Huber
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.1.20. **Ibalizumab** - **TROGARZO (CAP)** - **PSUSA/00010797/202009**

Applicant: Theratechnologies Europe Limited
PRAC Rapporteur: David Olsen
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.1.21. **Idebenone**\(^{12}\) - **RAXONE (CAP)** - **PSUSA/00010412/202009**

Applicant: Santhera Pharmaceuticals (Deutschland) GmbH
PRAC Rapporteur: Amelia Cupelli
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

\(^{11}\) Centrally authorised product(s) only
\(^{12}\) Centrally authorised product(s) only
6.1.22. **Influenza vaccine (live attenuated, nasal) - FLUENZ TETRA (CAP) - PSUSA/00001742/202008**

Applicant: AstraZeneca AB

PRAC Rapporteur: Jean-Michel Dogné

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

6.1.23. **Isatuximab - SARCLISA (CAP) - PSUSA/00010851/202009**

Applicant: Sanofi-aventis groupe

PRAC Rapporteur: Eva Segovia

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

6.1.24. **Isavuconazole - CRESEMBA (CAP) - PSUSA/00010426/202009**

Applicant: Basilea Pharmaceutica Deutschland GmbH

PRAC Rapporteur: Adam Przybylkowski

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

6.1.25. **Linaclotide - CONSTELLA (CAP) - PSUSA/00010025/202008**

Applicant: Allergan Pharmaceuticals International Limited

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

6.1.26. **Lorlatinib - LORVIQUA (CAP) - PSUSA/00010760/202009**

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

6.1.27. **Mecasermin - INCRELEX (CAP) - PSUSA/00001942/202008**

Applicant: Ipsen Pharma

PRAC Rapporteur: Kirsti Villikka

Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.28. Mepolizumab - NUCALA (CAP) - PSUSA/00010456/202009

Applicant: GlaxoSmithKline Trading Services Limited
PRAC Rapporteur: Brigitte Keller-Stanislawski
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.29. Meropenem, vaborbactam - VABOREM (CAP) - PSUSA/00010727/202008

Applicant: Menarini International Operations Luxembourg S.A.
PRAC Rapporteur: Maria del Pilar Rayon
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.30. Moroctocog alfa - REFACTO AF (CAP) - PSUSA/00002089/202008

Applicant: Pfizer Europe MA EEIG
PRAC Rapporteur: Anette Kirstine Stark
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.31. Naldemedine - RIZMOIC (CAP) - PSUSA/00010753/202009

Applicant: Shionogi B.V.
PRAC Rapporteur: Rhea Fitzgerald
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.32. Naloxegol - MOVENTIG (CAP) - PSUSA/00010317/202009

Applicant: Kyowa Kirin Holdings B.V.
PRAC Rapporteur: Rhea Fitzgerald
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.33. Naltrexone, bupropion - MYSIMBA (CAP) - PSUSA/00010366/202009

Applicant: Orexigen Therapeutics Ireland Limited
PRAC Rapporteur: Martin Huber
Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.34. Pandemic influenza vaccine (H5N1) (whole virion, vero cell derived, inactivated) - PANDEMIC INFLUENZA VACCINE H5N1 BAXTER (CAP) - PSUSA/00002282/202008

Applicant: Ology Bioservices Ireland Limited

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.35. Pembrolizumab - KEYTRUDA (CAP) - PSUSA/00010403/202009

Applicant: Merck Sharp & Dohme B.V.

PRAC Rapporteur: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.36. Raltegravir - ISENTRESS (CAP) - PSUSA/00010373/202009

Applicant: Merck Sharp & Dohme B.V.

PRAC Rapporteur: Adrien Inoubli

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.37. Risankizumab - SKYRIZI (CAP) - PSUSA/00010765/202009

Applicant: AbbVie Deutschland GmbH & Co. KG

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.38. Rivaroxaban - XARELTO (CAP) - PSUSA/00002653/202009

Applicant: Bayer AG

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP
<table>
<thead>
<tr>
<th>Section</th>
<th>Product Name</th>
<th>EMA/PRAC/Number</th>
<th>Applicant</th>
<th>PRAC Rapporteur</th>
<th>Scope</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.1.39</td>
<td>Sebelipase alfa - KANUMA (CAP) - PSUSA/00010422/202008</td>
<td></td>
<td>Alexion Europe SAS</td>
<td>Ulla Wändel Liminga</td>
<td>Evaluation of a PSUSA procedure</td>
<td>For adoption of recommendation to CHMP</td>
</tr>
<tr>
<td>6.1.40</td>
<td>Siponimod - MAYZENT (CAP) - PSUSA/00010818/202009</td>
<td></td>
<td>Novartis Europharm Limited</td>
<td>Maria del Pilar Rayon</td>
<td>Evaluation of a PSUSA procedure</td>
<td>For adoption of recommendation to CHMP</td>
</tr>
<tr>
<td>6.1.41</td>
<td>Sodium zirconium cyclosilicate - LOKELMA (CAP) - PSUSA/00010675/202009</td>
<td></td>
<td>AstraZeneca AB</td>
<td>Kirsti Villikka</td>
<td>Evaluation of a PSUSA procedure</td>
<td>For adoption of recommendation to CHMP</td>
</tr>
<tr>
<td>6.1.42</td>
<td>Solriamfetol - SUNOSI (CAP) - PSUSA/00010831/202009</td>
<td></td>
<td>Jazz Pharmaceuticals Ireland Limited</td>
<td>Julia Pallos</td>
<td>Evaluation of a PSUSA procedure</td>
<td>For adoption of recommendation to CHMP</td>
</tr>
<tr>
<td>6.1.43</td>
<td>Tasonermin - BEROMUN (CAP) - PSUSA/00002850/202008</td>
<td></td>
<td>Belpharma s.a.</td>
<td>Anette Kirstine Stark</td>
<td>Evaluation of a PSUSA procedure</td>
<td>For adoption of recommendation to CHMP</td>
</tr>
<tr>
<td>6.1.44</td>
<td>Teduglutide - REVESTIVE (CAP) - PSUSA/00009305/202008</td>
<td></td>
<td>Shire Pharmaceuticals Ireland Limited</td>
<td>Anette Kirstine Stark</td>
<td>Evaluation of a PSUSA procedure</td>
<td>For adoption of recommendation to CHMP</td>
</tr>
</tbody>
</table>
**Action:** For adoption of recommendation to CHMP

### 6.1.45. Tildrakizumab - ILUMETRI (CAP) - PSUSA/00010720/202009

**Applicant:** Almirall S.A  
**PRAC Rapporteur:** Adam Przybylkowski  
**Scope:** Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

### 6.1.46. Tobramycin\(^\text{13, 14}\) - VANTOBRA (CAP) - PSUSA/00010370/202009

**Applicant:** PARI Pharma GmbH  
**PRAC Rapporteur:** Ulla Wändel Liminga  
**Scope:** Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

### 6.1.47. Trabectedin - YONDELIS (CAP) - PSUSA/00003001/202009

**Applicant:** Pharma Mar, S.A.  
**PRAC Rapporteur:** Anette Kirstine Stark  
**Scope:** Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

### 6.1.48. Velmanase alfa - LAMZEDE (CAP) - PSUSA/00010677/202009

**Applicant:** Chiesi Farmaceutici S.p.A.  
**PRAC Rapporteur:** Jan Neuhauser  
**Scope:** Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

### 6.2. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) and nationally authorised products (NAPs)

**6.2.1. Anagrelide - ANAGRELIDE MYLAN (CAP); XAGRID (CAP); NAP - PSUSA/00000208/202009**

**Applicants:** Mylan S.A.S (Anagrelide Mylan), Shire Pharmaceuticals Ireland Limited (Xagrid), various

\(^{13}\) Nebuliser solution  
\(^{14}\) Centrally authorised product(s) only
PRAC Rapporteur: Tiphaine Vaillant
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

### 6.2.2. Glycopyrronium\(^{15}\) - SIALANAR (CAP); NAP - PSUSA/00010529/202009

Applicants: Proveca Pharma Limited (Sialanar), various
PRAC Rapporteur: Zane Neikena
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

### 6.2.3. Trientine - CUFENCE (CAP); CUPRIOR (CAP); NAP - PSUSA/00010637/202009

Applicants: Orphalan (Cuprior), Univar Solutions BV (Cufence), various
PRAC Rapporteur: Ana Sofia Diniz Martins
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

### 6.2.4. Zoledronic acid\(^{16}\) - ZOLEDRONIC ACID HOSPIRA (CAP); ZOLEDRONIC ACID MEDAC (CAP); ZOMETA (CAP); NAP - PSUSA/00003149/202008

Applicants: Medac Gesellschaft für klinische Spezialpräparate mbH (Zoledronic acid medac), Novartis Europharm Limited (Zometa), Pfizer Europe MA EEIG (Zoledronic acid Hospira), various
PRAC Rapporteur: Anette Kirstine Stark
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

### 6.3. PSUR single assessment (PSUSA) procedures including nationally authorised products (NAPs) only

#### 6.3.1. Bromazepam (NAP) - PSUSA/00000435/202008

Applicant(s): various
PRAC Lead: Tiphaine Vaillant
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CMDh

---

\(^{15}\) Treatment of severe sialorrhea (chronic pathological drooling) indication(s) only
\(^{16}\) Treatment of cancer and fractures indication(s) only
6.3.2. Dalteparin sodium (NAP) - PSUSA/00000922/202008

Applicant(s): various
PRAC Lead: Rugilė Pilvinienė
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CMDh

6.3.3. Dermatophagoides pteronyssinus, dermatophagoides farina\(^{17}\)\(^{18}\)\(^{19}\) (NAP) - PSUSA/00010582/202009

Applicant(s): various
PRAC Lead: Brigitte Keller-Stanislawski
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CMDh

6.3.4. Dexamfetamine (NAP) - PSUSA/00000986/202009

Applicant(s): various
PRAC Lead: Ana Sofia Diniz Martins
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CMDh

6.3.5. Dexibuprofen (NAP) - PSUSA/00000996/202008

Applicant(s): various
PRAC Lead: Jan Neuhauser
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CMDh

6.3.6. Hexoprenaline sulfate (NAP) - PSUSA/00003170/202008

Applicant(s): various
PRAC Lead: Roxana Dondera
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CMDh

6.3.7. Metronidazole, neomycin, nystatin (NAP) - PSUSA/00010508/202009

Applicant(s): various

\(^{17}\) Allergen for therapy
\(^{18}\) For oromucosal use only
\(^{19}\) Medicinal product(s) authorised via mutually recognition procedure and decentralised procedure only
PRAC Lead: Roxana Dondera
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CMDh

6.3.8. Modafinil (NAP) - PSUSA/00010242/202008

Applicant(s): various
PRAC Lead: Martin Huber
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CMDh

6.3.9. Nifedipine (NAP) - PSUSA/00002156/202008

Applicant(s): various
PRAC Lead: Menno van der Elst
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CMDh

6.3.10. Oxcarbazepine (NAP) - PSUSA/00002235/202008

Applicant(s): various
PRAC Lead: Anette Kirstine Stark
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CMDh

6.3.11. Pefloxacin (NAP) - PSUSA/00002322/202008

Applicant(s): various
PRAC Lead: Gabriela Jazbec
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CMDh

6.3.12. Permethrin (NAP) - PSUSA/00002355/202008

Applicant(s): various
PRAC Lead: Martin Huber
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CMDh
6.3.13. **Phenytoin (NAP) - PSUSA/00002392/202008**

Applicant(s): various  
PRAC Lead: Ronan Grimes  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CMDh

6.3.14. **Poractant alfa (NAP) - PSUSA/00002478/202008**

Applicant(s): various  
PRAC Lead: Kirsti Villikka  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CMDh

6.3.15. **Suxamethonium (NAP) - PSUSA/00002834/202008**

Applicant(s): various  
PRAC Lead: Nikica Mirošević Skvrce  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CMDh

6.4. **Follow-up to PSUR/PSUSA procedures**

6.4.1. **Docetaxel - TAXOTERE (CAP) - EMEA/H/C/000073/LEG 039**

Applicant: Sanofi Mature IP  
PRAC Rapporteur: Tiphaine Vaillant  
Scope: Detailed review on the potential risk for decreased efficacy of docetaxel when used along with any selective cyclooxygenase-2 (Cox-2) inhibitors as requested in the conclusions of the PSUR single assessment (PSUSA) procedure (PSUSA/00001152/201911) adopted in July 2020  
**Action:** For adoption of advice to CHMP

6.4.2. **Pregabalin - LYRICA (CAP) - EMEA/H/C/000546/LEG 054**

Applicant: Upjohn EESV  
PRAC Rapporteur: Liana Gross-Martirosyan  
Scope: Detailed review of cases reporting suicidal action, behaviour or ideation as requested in the conclusions of the PSUR single assessment (PSUSA) procedure (PSUSA/00002511/202001) adopted in September 2020  
**Action:** For adoption of advice to CHMP
6.4.3. Pregabalin - PREGABALIN PFIZER (CAP) - EMEA/H/C/003880/LEG 007

Applicant: Upjohn EESV
PRAC Rapporteur: Liana Gross-Martirosyan
Scope: Detailed review of cases reporting suicidal action, behaviour or ideation as requested in the conclusions of the PSUR single assessment (PSUSA) procedure (PSUSA/00002511/202001) adopted in September 2020

Action: For adoption of advice to CHMP

6.5. Variation procedure(s) resulting from PSUSA evaluation

6.5.1. COVID-19 mRNA\(^{20}\) vaccine (nucleoside-modified) - COMIRNATY (CAP) - EMEA/H/C/005735/II/0016/G

Applicant: BioNTech Manufacturing GmbH
PRAC Rapporteur: Menno van der Elst
Scope: Grouped variation consisting of: 1) update of section 4.8 SmPC to add ‘diarrhea’ and ‘vomiting’ as adverse drug reactions (ADRs) with frequencies and update the ADR ‘pain in extremity’ in order to fulfill MEA 002.1 concluded in February 2021; 2) update of section 4.8 SmPC to update the ADR ‘hypersensitivity reactions’ in more detail with the relevant frequency categories in order to fulfill LEG 022.1. The package leaflet is updated accordingly.

In addition, the MAH took the opportunity to perform editorial changes in section 6.6 of the SmPC

Action: For adoption of PRAC Assessment Report

6.5.2. Ocrelizumab - OCREVUS (CAP) - EMEA/H/C/004043/II/0024

Applicant: Roche Registration GmbH
PRAC Rapporteur: Brigitte Keller-Stanislawski
Scope: Update of section 4.4 of the SmPC to amend the wording on progressive multifocal leukoencephalopathy (PML) as requested in the conclusions of the latest periodic safety update report single assessment (PSUSA) procedure (PSUSA/00010662/202003) adopted in November 2020

Action: For adoption of PRAC Assessment Report

\(^{20}\) Messenger ribonucleic acid
6.6. Expedited summary safety reviews\textsuperscript{21}

6.6.1. Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (previously COVID-19 VACCINE ASTRazeneca) (CAP) - EMEA/H/C/005675/LEG 036

Applicant: AstraZeneca AB
PRAC Rapporteur: Jean-Michel Dogné

Scope: Cumulative review of cases of hypersensitivity as per the conclusions of the signal procedure (EPITT 19668) adopted in March 2021

Action: For adoption of advice to CHMP

7. Post-authorisation safety studies (PASS)

7.1. Protocols of PASS imposed in the marketing authorisation(s)\textsuperscript{22}

7.1.1. Cabotegravir - VOCABRIA (CAP); rilpivirine - REKAMBYS (CAP) - EMEA/H/C/PSP/J/0092

Applicant(s): Janssen-Cilag International N.V. (Rekambys), ViiV Healthcare B.V. (Vocabria)
PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Protocol for a joint drug utilisation study (DUS) to assess adherence, effectiveness and resistance: a prospective observational cohort study in people living with human immunodeficiency virus (HIV) (PLWH) initiating antiretroviral (ARV) regimen of cabotegravir (CAB) + rilpivirine (RPV) long-acting (LA) in collaboration with EuroSIDA\textsuperscript{23}

Action: For adoption of PRAC Assessment Report, PRAC outcome letter

7.1.2. Direct acting antivirals (DAAV): Dasabuvir - EXVIERA (CAP); elbasvir, grazoprevir - ZEPATIER (CAP); glecaprevir, pibrentasvir - MAVIRET (CAP); ledipasvir, sofosbuvir - HARVONI (CAP); ombitasvir, peribrevir, ritonavir - VIEKIRAX (CAP); sofosbuvir - SOVALDI (CAP); sofosbuvir, velpatasvir - EPCLUSA (CAP); sofosbuvir, velpatasvir, voxilaprevir - VOSEVI (CAP) - EMEA/H/C/PSA/J/0068

Applicant(s): Gilead Science International (on behalf of a consortium)
PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Substantial amendment for a joint protocol previously agreed in June 2020 (PSA/J/0028.1) for a non-interventional imposed PASS on early recurrence of hepatocellular carcinoma (HCC) in hepatitis C virus (HCV)-infected patients after direct-acting antiviral (DAAV) therapy in order to estimate the risk of early HCC recurrence associated with DAAV

\textsuperscript{21} Submission of expedited summary safety reports for review in addition to the requirements for submission of PSUR(s) falling within the pandemic period and requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC

\textsuperscript{22} In accordance with Article 107n of Directive 2001/83/EC

\textsuperscript{23} Prospective observational pan-European cohort study
therapy exposure relative to no DAAV therapy exposure during routine clinical care of HCV-infected patients with successfully treated HCC, as required in the outcome of the referral procedure under Article 20 of Regulation (EC) No 726/2004 on DAAV indicated for treatment of hepatitis C (interferon-free) completed in December 2016 (EMEA/H/A-20/1438)

**Action:** For adoption of PRAC Assessment Report, PRAC outcome letter

### 7.1.3. Pitolisant - WAKIX (CAP) - EMEA/H/C/PSA/S/0060.1

**Applicant:** Bioprojet Pharma

**PRAC Rapporteur:** Kirsti Villikka

**Scope:** MAH's response to PSA/S/0060 [substantial amendment to a protocol previously agreed in September 2016 for a 5-year multicentre, observational PASS to document the utilisation of Wakix (pitolisant) in the treatment of narcolepsy with or without cataplexy and to collect information on its long-term safety when used in routine medical practice] as per the request for supplementary information (RSI) adopted in December 2020

**Action:** For adoption of PRAC Assessment Report, PRAC outcome letter

### 7.1.4. Sotagliflozin – ZYNQUISTA (CAP) - EMEA/H/C/PSP/S/0084.4

**Applicant:** Guidehouse Germany GmbH

**PRAC Rapporteur:** Martin Huber

**Scope:** MAH’s response to PSP/S/0084.3 [protocol for an observational retrospective cohort study using existing data sources on the incidence of diabetic ketoacidosis (DKA) in adult patients with type 1 diabetes mellitus (T1DM) treated with sotagliflozin as an adjunct to insulin versus insulin alone, as required in the outcome of the initial opinion/marketing authorisation (EMEA/H/C/004889) finalised in February 2019] as per the request for supplementary information (RSI) adopted in December 2020

**Action:** For adoption of PRAC Assessment Report, PRAC outcome letter

### 7.2. Protocols of PASS non-imposed in the marketing authorisation(s)

#### 7.2.1. Cabotegravir - VOCABRIA (CAP) - EMEA/H/C/004976/MEA 004

**Applicant:** ViiV Healthcare B.V.

**PRAC Rapporteur:** Martin Huber

**Scope:** Protocol for study 215162 (listed as a category 3 study in the RMP): a prospective observational cohort study to monitor for hepatotoxicity and regimen discontinuation due to liver related adverse events among patients initiating cabotegravir-containing antiretroviral regimen. Summary objectives [final clinical study report (CSR): expected in March 2027]

**Action:** For adoption of advice to CHMP

---

24 In accordance with Article 107m of Directive 2001/83/EC, supervised by PRAC in accordance with Article 61a (6) of Regulation (EC) No 726/2004
### 7.2.2. Cabotegravir - VOCABRIA (CAP) - EMEA/H/C/004976/MEA 005

**Applicant:** ViiV Healthcare B.V.

**PRAC Rapporteur:** Martin Huber

**Scope:** Protocol for study 215163: a study on pregnancy and neonatal outcomes following prenatal exposure to cabotegravir long acting (CAB LA) – data from the European Pregnancy and Paediatric human immunodeficiency virus (HIV) Cohort Collaboration (EPPICC)

**Action:** For adoption of advice to CHMP

### 7.2.3. Cabotegravir - VOCABRIA (CAP) - EMEA/H/C/004976/MEA 006

**Applicant:** ViiV Healthcare B.V.

**PRAC Rapporteur:** Martin Huber

**Scope:** Protocol for study 215325: a study on pregnancy and neonatal outcomes following prenatal exposure to cabotegravir - data from the Antiretroviral Pregnancy Registry (APR)

**Action:** For adoption of advice to CHMP

### 7.2.4. Coronavirus (COVID-19) mRNA\(^{25}\) vaccine (nucleoside-modified) - COMIRNATY (CAP) - EMEA/H/C/005735/MEA 017

**Applicant:** BioNTech Manufacturing GmbH

**PRAC Rapporteur:** Menno van der Elst

**Scope:** Protocol for study vACCine Covid-19 monitoring readinESS (ACCESS)/Vaccine monitoring Collaboration for Europe (VAC4EU): an assessment of occurrence of safety events of interest, including severe or atypical COVID-19 in real-world use of COVID-19 mRNA vaccine [final clinical study report (CSR): expected in January 2024] (from initial opinion/marketing authorisation)

**Action:** For adoption of advice to CHMP

### 7.2.5. Darbepoetin alfa - ARANESP (CAP) - EMEA/H/C/000332/MEA 092.2

**Applicant:** Amgen Europe B.V.

**PRAC Rapporteur:** Martin Huber

**Scope:** MAH’s response to MEA 092.1 [protocol for study 20190404: a retrospective cohort study to assess the use of erythropoiesis stimulating agents (ESAs) in subjects receiving myelosuppressive chemotherapy in Europe] as per the request for supplementary information (RSI) adopted in November 2020

**Action:** For adoption of advice to CHMP

\(^{25}\) Messenger ribonucleic acid
7.2.6. **Dimethyl fumarate - TECFIDERA (CAP) - EMEA/H/C/002601/MEA 007.2**

**Applicant:** Biogen Netherlands B.V.  
**PRAC Rapporteur:** Martin Huber  
**Scope:** Amendment to a protocol previously agreed in October 2020 to study 109MS401 (ESTEEM): a multicentre, global, observational study to collect information on safety and to document the drug utilisation of Tecfidera (dimethyl fumarate) when used in routine medical practice in the treatment of relapsing multiple sclerosis  
**Action:** For adoption of advice to CHMP

7.2.7. **Fenofibrate, pravastatin sodium - PRAVAFENIX (CAP) - EMEA/H/C/001243/MEA 007.6**

**Applicant:** Laboratoires SMB s.a.  
**PRAC Rapporteur:** Adrien Inoubli  
**Scope:** Amendment to a protocol previously agreed in 2014 for study POSE (Pravafenix Observational Study in Europe) (EUPAS13661): a European, observational, three-year cohort comparative study on the safety of the fixed dose combination pravastatin 40 mg/fenofibrate 160 mg (Pravafenix) versus statin alone in real clinical practice  
**Action:** For adoption of advice to CHMP

7.2.8. **Inotersen - TEGSEDI (CAP) - EMEA/H/C/004782/MEA 001.5**

**Applicant:** Akcea Therapeutics Ireland Limited  
**PRAC Rapporteur:** Rhea Fitzgerald  
**Scope:** Amendment to a protocol previously agreed in September 2020 for study TEG4001: a prospective, non-interventional, long-term, multinational cohort safety study of patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)  
**Action:** For adoption of advice to CHMP

7.2.9. **Sotagliflozin - ZYNQUISTA (CAP) - EMEA/H/C/004889/MEA 004.3**

**Applicant:** Guidehouse Germany GmbH  
**PRAC Rapporteur:** Martin Huber  
**Scope:** MAH’s response to MEA 004.2 [protocol for a nested, case-control study to evaluate the risk of malignancies (bladder, renal, breast, Leydig cell, pancreatic, thyroid and prostate cancers) in adult patients with type 1 diabetes mellitus (T1DM) using sotagliflozin in existing healthcare databases in Europe and in the United States [final clinical study report (CSR) expected in April 2030]] as per the request for supplementary information (RSI) adopted in October 2020  
**Action:** For adoption of advice to CHMP
7.2.10. **Tofacitinib - XELJANZ (CAP) - EMEA/H/C/004214/MEA 015.2**

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Amendment to a protocol previously agreed in November 2020 for study A3921334 (listed as a category 3 study in the RMP): a non-interventional PASS to evaluate the effectiveness of additional risk minimisation measures (aRMM) materials for Xeljanz (tofacitinib) in Europe via a survey of healthcare professionals (HCPs), as requested in the conclusions of the referral procedure under Article 20 of Regulation (EC) No 726/2004 (EMEA/H/A-20/1485) finalised in November 2019

**Action:** For adoption of advice to CHMP

7.3. **Results of PASS imposed in the marketing authorisation(s)**

7.3.1. **Aprotinin (NAP) - EMEA/H/N/PSR/S/0030**

Applicant: Nordic Group BV (Trasylol)

PRAC Rapporteur: Laurence de Fays

Scope: Results for a Nordic aprotinin patient registry to record utilisation information on patients at cardiac surgery centres

**Action:** For adoption of recommendation to CMDh (or request for supplementary information (RSI))

7.3.2. **Dexamfetamine (NAP) - EMEA/H/N/PSR/S/0028**

Applicant: Medice Arzneimittel Pütter GmbH & Co. KG

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Results of a PASS to evaluate the long-term safety of dexamfetamine to assess the incidence proportion and incidence rate for cardiovascular, psychiatric, growth and sexual maturity related adverse events in children with a diagnosis of attention deficit hyperactivity disorder (ADHD) who have been treated with dexamfetamine, methylphenidate or lisdexamfetamine as recorded in healthcare databases of three countries. The study also compares the risk of long-term cardiovascular, psychiatric, growth and sexual maturity-related adverse events of dexamfetamine versus methylphenidate or lisdexamfetamine in each database

**Action:** For adoption of recommendation to CMDh (or request for supplementary information (RSI))

7.3.3. **Dexamfetamine (NAP) - EMEA/H/N/PSR/S/0029**

Applicant: Medice Arzneimittel Pütter GmbH & Co. KG

PRAC Rapporteur: Ana Sofia Diniz Martins

---

26 In accordance with Article 107p-q of Directive 2001/83/EC
Scope: Results of a drug utilisation study (DUS) to collect data on abuse, misuse, overdose, diversion and dependence related to dexamfetamine in five European countries

**Action:** For adoption of recommendation to CMDh (or request for supplementary information (RSI))

### 7.4. Results of PASS non-imposed in the marketing authorisation(s)


Applicant: AstraZeneca AB

PRAC Rapporteur: Annika Folin

Scope: Submission of the final report from studies MB102103, MB102104 and MB102110 listed as a category 3 study in the RMP. These are observational studies comparing the risk of severe complications of UTI, acute liver injury and acute kidney injury respectively, between patients with Type 2 Diabetes exposed to dapagliflozin and those exposed to other antidiabetic treatments. The RMP version 23.1 for Forxiga and Edistride has also been submitted

**Action:** For adoption of PRAC Assessment Report

#### 7.4.2. Human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed) - GARDASIL (CAP) - EMEA/H/C/000703/II/0091

Applicant: MSD Vaccins

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Submission of the final report from study V501-070 (listed as a category 3 study in the RMP): a post-licensure observational study of the safety of Gardasil (human papillomavirus vaccine) in males. The RMP (version 14.1) is updated accordingly. The MAH took the opportunity to update the RMP with the synopsis for the study protocol for an observational study combining health-registries in Sweden on the 2-dose effectiveness of Gardasil (human papillomavirus vaccine) as agreed in MEA 82.6 by the CHMP in June 2020

**Action:** For adoption of PRAC Assessment Report

#### 7.4.3. Insulin detemir - LEVEMIR (CAP) - EMEA/H/C/000528/II/0101

Applicant: Novo Nordisk A/S

PRAC Rapporteur: Anette Kirstine Stark

Scope: Update of sections 4.6 and 5.1 of the SmPC in order to update information on pregnancy, based on final results from non-interventional study NN304-4016 (listed as a category 3 study in the RMP): a diabetes pregnancy registry study conducted to assess the long-term safety of insulin use in pregnant women. The RMP (version 21.0) is updated accordingly

---

27 In accordance with Article 61a (6) of Regulation (EC) No 726/2004, in line with the revised variations regulation for any submission as of 4 August 2013
**Action:** For adoption of PRAC Assessment Report

### 7.4.4. Linaclotide - CONSTELLA (CAP) - EMEA/H/C/002490/II/0053

Applicant: Allergan Pharmaceuticals International Limited  
PRAC Rapporteur: Martin Huber  
Scope: Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on intestinal perforation and to add gastrointestinal perforation to the list of adverse drug reactions (ADRs) with frequency rare based on the Truven MarketScan\(^{28}\) study and as requested by the PRAC in the conclusions of LEG 15.1 adopted in December 2020 [as requested in the conclusions of the PSUR single assessment (PSUSA) procedure (PSUSA/00010025/201908) adopted in March 2020]. The MAH took the opportunity to update the list of local representatives in the package leaflet  
**Action:** For adoption of PRAC Assessment Report

### 7.5. Interim results of imposed and non-imposed PASS submitted before the entry into force of the revised variation regulation

#### 7.5.1. Adalimumab - AMGEVITA (CAP) - EMEA/H/C/004212/MEA 001.2

Applicant: Amgen Europe B.V.  
PRAC Rapporteur: Ulla Wändel Liminga  
Scope: First interim report for study 20160264 (ABP 501) - British Society of Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR): an observational study to evaluate long term safety of Amgevita (adalimumab) in patients with rheumatoid arthritis [final report: expected in Q3 2027]  
**Action:** For adoption of advice to CHMP

#### 7.5.2. Deferasirox - EXJADE (CAP) - EMEA/H/C/000670/ANX 038.12

Applicant: Novartis Europharm Limited  
PRAC Rapporteur: Tiphaine Vaillant  
Scope: Seventh annual interim report for study CICL670E2422: an observational, multicentre cohort study to evaluate the long-term exposure and safety of deferasirox in the treatment of paediatric non-transfusion dependent thalassaemia patients over 10 years old for whom deferoxamine is contraindicated or inadequate  
**Action:** For adoption of advice to CHMP

---

\(^{28}\) Truven MarketScan claims database used to assess the potential association between linaclotide and gastrointestinal (GI) perforation
7.5.3. Fenofibrate, pravastatin sodium - PRAVAFENIX (CAP) - EMEA/H/C/001243/MEA 007.7

Applicant: Laboratoires SMB s.a.
PRAC Rapporteur: Adrien Inoubli

Scope: Interim results for study POSE (Pravafenix Observational Study in Europe) (EUPAS13661): a European, observational, three-year cohort comparative study on the safety of the fixed dose combination pravastatin 40 mg/ fenofibrate 160 mg (Pravafenix) versus statin alone in real clinical practice

Action: For adoption of advice to CHMP

7.5.4. Golimumab - SIMPONI (CAP) - EMEA/H/C/000992/MEA 033.5

Applicant: Janssen Biologics B.V.
PRAC Rapporteur: Ulla Wändel Liminga

Scope: Third annual interim report for study MK-8259-050 (version 2.0) (listed as a category 3 study in the RMP): an observational PASS for golimumab in the treatment of poly-articular juvenile idiopathic arthritis (pJIA) using the German Biologics JIA registry (BiKeR)

Action: For adoption of advice to CHMP

7.5.5. Infliximab - REMICADE (CAP) - EMEA/H/C/000240/MEA 114.11

Applicant: Janssen Biologics B.V.
PRAC Rapporteur: Ulla Wändel Liminga

Scope: Interim report for study C0168Z03 (PSOLAR: PSOriasis Longitudinal Assessment and Registry): a multicentre, open study of patients with plaque psoriasis who are candidates for systemic therapy including biologics [final clinical study report (CSR) for PSOLAR expected in June 2023]

Action: For adoption of advice to CHMP

7.6. Others

7.6.1. Acalabrutinib - CALQUENCE (CAP) - EMEA/H/C/005299/MEA 002

Applicant: AstraZeneca AB
PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: Protocol for study D8220C00008 (listed as a category 3 study in the RMP): a phase 3b, multicentre, open-label, single-arm study in subjects with chronic lymphocytic leukaemia (ASSURE) to address missing information around moderate to severe cardiac impaired patients in subjects treated with Calquence (acalabrutinib)

Action: For adoption of advice to CHMP
7.6.2. **Melatonin - SLENYTO (CAP) - EMEA/H/C/004425/REC 002.1**

Applicant: RAD Neurim Pharmaceuticals EEC SARL

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Second annual French ‘recommendation temporaire d’utilisation (RTU)’ report on special temporary recommendation of use for Circadin (melatonin) 2-6 mg in the autism spectrum disorder (ASD) and neurogenetic 6-18 year-old population for the period from October 2015 to July 2019

**Action:** For adoption of advice to CHMP

7.7. **New Scientific Advice**

None

7.8. **Ongoing Scientific Advice**

None

7.9. **Final Scientific Advice (Reports and Scientific Advice letters)**

None

8. **Renewals of the marketing authorisation, conditional renewal and annual reassessments**

8.1. **Annual reassessments of the marketing authorisation**

None

8.2. **Conditional renewals of the marketing authorisation**

8.2.1. **Ataluren - TRANSLARNA (CAP) - EMEA/H/C/002720/R/0061 (without RMP)**

Applicant: PTC Therapeutics International Limited

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Conditional renewal of the marketing authorisation

**Action:** For adoption of advice to CHMP

8.2.2. **Belantamab mafodotin - BLENREP (CAP) - EMEA/H/C/004935/R/0003 (without RMP)**

Applicant: GlaxoSmithKline (Ireland) Limited

PRAC Rapporteur: Annika Folin
Scope: Conditional renewal of the marketing authorisation

**Action:** For adoption of advice to CHMP

### 8.2.3. Bulevirtide - HEPCLUDEX (CAP) - EMEA/H/C/004854/R/0003 (without RMP)

Applicant: MYR GmbH
PRAC Rapporteur: Adam Przybylkowski
Scope: Conditional renewal of the marketing authorisation

**Action:** For adoption of advice to CHMP

### 8.2.4. Entrectinib - ROZLYTREK (CAP) - EMEA/H/C/004936/R/0002 (without RMP)

Applicant: Roche Registration GmbH
PRAC Rapporteur: Menno van der Elst
Scope: Conditional renewal of the marketing authorisation

**Action:** For adoption of advice to CHMP

### 8.2.5. Imlifidase - IDEFIRIX (CAP) - EMEA/H/C/004849/R/0003 (without RMP)

Applicant: Hansa Biopharma AB
PRAC Rapporteur: Menno van der Elst
Scope: Conditional renewal of the marketing authorisation

**Action:** For adoption of advice to CHMP

### 8.2.6. Pretomanid - DOVPRELA (CAP) - EMEA/H/C/005167/R/0005 (without RMP)

Applicant: Mylan IRE Healthcare Limited
PRAC Rapporteur: Liana Gross-Martirosyan
Scope: Conditional renewal of the marketing authorisation

**Action:** For adoption of advice to CHMP

### 8.3. Renewals of the marketing authorisation

#### 8.3.1. Bortezomib - BORTEZOMIB SUN (CAP) - EMEA/H/C/004076/R/0015 (without RMP)

Applicant: Sun Pharmaceutical Industries Europe B.V.
PRAC Rapporteur: Amelia Cupelli
Scope: 5-year renewal of the marketing authorisation

**Action:** For adoption of advice to CHMP
8.3.2. Enoxaparin sodium - INHIXA (CAP) - EMEA/H/C/004264/R/0076 (with RMP)

Applicant: Techdow Pharma Netherlands B.V.
PRAC Rapporteur: Menno van der Elst
Scope: 5-year renewal of the marketing authorisation
Action: For adoption of advice to CHMP

8.3.3. Glycopyrronium - SIALANAR (CAP) - EMEA/H/C/003883/R/0018 (without RMP)

Applicant: Proveca Pharma Limited
PRAC Rapporteur: Zane Neikena
Scope: 5-year renewal of the marketing authorisation
Action: For adoption of advice to CHMP

8.3.4. Lenvatinib - KISPLYX (CAP) - EMEA/H/C/004224/R/0043 (without RMP)

Applicant: Eisai GmbH
PRAC Rapporteur: David Olsen
Scope: 5-year renewal of the marketing authorisation
Action: For adoption of advice to CHMP

8.3.5. Methotrexate - NORDIMET (CAP) - EMEA/H/C/003983/R/0018 (without RMP)

Applicant: Nordic Group B.V.
PRAC Rapporteur: Martin Huber
Scope: 5-year renewal of the marketing authorisation
Action: For adoption of advice to CHMP

8.3.6. Sildenafil - MYSILDECARD (CAP) - EMEA/H/C/004186/R/0009 (without RMP)

Applicant: Mylan S.A.S
PRAC Rapporteur: Menno van der Elst
Scope: 5-year renewal of the marketing authorisation
Action: For adoption of advice to CHMP

8.3.7. Vismodegib - ERIVEDGE (CAP) - EMEA/H/C/002602/R/0050 (without RMP)

Applicant: Roche Registration GmbH
PRAC Rapporteur: Annika Folin
Scope: 5-year renewal of the marketing authorisation
Action: For adoption of advice to CHMP

9. Product related pharmacovigilance inspections

9.1. List of planned pharmacovigilance inspections

None

9.2. Ongoing or concluded pharmacovigilance inspections

Disclosure of information on results of pharmacovigilance inspections could undermine the protection of the purpose of these inspections, investigations and audits. Therefore such information is not reported in the agenda.

9.3. Others

None

10. Other safety issues for discussion requested by the CHMP or the EMA

10.1. Safety related variations of the marketing authorisation

None

10.2. Timing and message content in relation to Member States’ safety announcements

None

10.3. Other requests

None

10.4. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.
11. Other safety issues for discussion requested by the Member States

11.1. Safety related variations of the marketing authorisation

None

11.2. Other requests

11.2.1. Dinoprostone (NAP) - SE/H/PSUFU/00001104/201909

Applicant(s): Ferring (Propess), Pfizer (Minoprostin, Prepidil, Prostaglandin E2 Pfizer, Prostin E2)

PRAC Lead: Annika Folin

Scope: Second PRAC consultation on a PSUR follow-up (PSU FU) procedure on risk minimisation measures to further minimise the risk of uterine hyperstimulation, including serious complications as uterine rupture, foetal and neonatal death and uterine haemorrhage, as discussed at PRAC and agreed by CMDh following the conclusion of the PSUSA procedure (PSUSA/00001104/201909) concluded in May 2020, and following advice on from PRAC adopted in December 2020, on request of Sweden

Action: For adoption of advice to Member States

11.2.2. Phenobarbital (NAP) - EE/H/PSUFU/00002370/202001

Applicant(s): Accord UK Limited (Phenobarbital Accord), Bausch Health Companies (Sevenaletta), Bayer (Phenobarbital), Bial (Bialminal), Desitin Arzneimittel GmbH (Luminal, Phenaemaletten, Phenaemal), Dompe Farmaceutici S.p.A. (Luminale), Kern Pharma S.L. (Luminal), Sanofi, Stada, Takeda (Fenemal), Teva

PRAC Lead: Maia Uusküla

Scope: PRAC consultation on a PSUR follow-up (PSU FU) procedure on a review of recent studies on major congenital malformations following exposure to phenobarbital in utero, on neurodevelopmental disorders, on the use of phenobarbital during pregnancy and on the need for additional risk minimisation measures, as discussed at PRAC and agreed by CMDh following the conclusion of the PSUSA procedure (PSUSA/00002370/202001) concluded in October 2020, on request of Estonia

Action: For adoption of advice to Member States
12. Organisational, regulatory and methodological matters

12.1. Mandate and organisation of the PRAC

12.1.1. PRAC working group - Best practice guide on using PRAC plenary time efficiently and effectively - update on the implementation of quantitative goals - Q1 2021

**Action:** For discussion

12.2. Coordination with EMA Scientific Committees or CMDh-v

None

12.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

None

12.4. Cooperation within the EU regulatory network

12.4.1. Coronavirus (COVID-19) pandemic - update

**Action:** For discussion

12.4.2. Heads of Medicines Agencies (HMA)-EMA joint big data - Big data steering group: data standards strategy initiative - call for expressions of interest

**Action:** For discussion

12.4.3. Joint advisory board (JAB) for COVID-19 vaccines studies - call for expressions of interest

**Action:** For discussion

12.4.4. PRAC strategic review and learning meeting (SRLM) under the Portuguese presidency of the European Union (EU) Council - Remote meeting, 23 April 2021 - agenda

PRAC lead: Ana Sofia Diniz Martins, Marcia Sofia Sanches de Castro Lopes Silva

**Action:** For discussion

12.5. Cooperation with International Regulators

None
12.6. **Contacts of the PRAC with external parties and interaction with the Interested Parties to the Committee**

None

12.7. **PRAC work plan**

None

12.8. **Planning and reporting**

12.8.1. Marketing authorisation applications (MAA) forecast for 2021 - planning update dated Q1 2021

*Action:* For discussion

12.8.2. PRAC workload statistics - Q1 2021

*Action:* For discussion

12.9. **Pharmacovigilance audits and inspections**

12.9.1. Pharmacovigilance systems and their quality systems

None

12.9.2. Pharmacovigilance inspections

None

12.9.3. Pharmacovigilance audits

None

12.10. **Periodic safety update reports (PSURs) & Union reference date (EURD) list**

12.10.1. Periodic safety update reports

None

12.10.2. **Granularity and Periodicity Advisory Group (GPAG)**

PRAC Lead: Menno van der Elst, Maia Uusküla

*Action:* For discussion
### 12.10.3. PSURs repository

None

### 12.10.4. Union reference date list - consultation on the draft list

**Action:** For adoption

### 12.11. Signal management


PRAC Lead: Menno van der Elst

**Action:** For discussion

### 12.12. Adverse drug reactions reporting and additional reporting

#### 12.12.1. Management and reporting of adverse reactions to medicinal products

None

#### 12.12.2. Additional monitoring

None

#### 12.12.3. List of products under additional monitoring - consultation on the draft list

**Action:** For adoption

### 12.13. EudraVigilance database

#### 12.13.1. Activities related to the confirmation of full functionality

None

### 12.14. Risk management plans and effectiveness of risk minimisations

#### 12.14.1. Risk management systems

None
12.14.2. Tools, educational materials and effectiveness measurement of risk minimisations

None

12.15. Post-authorisation safety studies (PASS)

12.15.1. Post-authorisation Safety Studies - imposed PASS

None

12.15.2. Post-authorisation Safety Studies - non-imposed PASS

None

12.16. Community procedures

12.16.1. Referral procedures for safety reasons

None

12.17. Renewals, conditional renewals, annual reassessments

None

12.18. Risk communication and transparency

12.18.1. Public participation in pharmacovigilance

None

12.18.2. Safety communication

None

12.19. Continuous pharmacovigilance

12.19.1. Incident management

None
12.20. Others

12.20.1. Real world data (RWE) use in marketing authorisation applications and extensions of indications - EMA study preliminary results

Action: For discussion

12.20.2. Video conferencing tool - WebEx rollout plan for PRAC

Action: For discussion

13. Any other business
14. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

EU Referral procedures for safety reasons: Urgent EU procedures and Other EU referral procedures
(Items 2 and 3 of the PRAC agenda)

A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the European Union (EU). For further detailed information on safety related referrals please see: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000150.jsp&mid=WC0b01ac05800240d0

Signals assessment and prioritisation
(Item 4 of the PRAC agenda)

A safety signal is information on a new or incompletely documented adverse event that is potentially caused by a medicine and that warrants further investigation. Signals are generated from several sources such as spontaneous reports, clinical studies and the scientific literature. The evaluation of safety signals is a routine part of pharmacovigilance and is essential to ensuring that regulatory authorities have a comprehensive knowledge of a medicine’s benefits and risks.

The presence of a safety signal does not mean that a medicine has caused the reported adverse event. The adverse event could be a symptom of another illness or caused by another medicine taken by the patient.

The evaluation of safety signals is required to establish whether or not there is a causal relationship between the medicine and the reported adverse event.

The evaluation of safety signals may not necessarily conclude that the medicine caused the adverse event in question. In cases where a causal relationship is confirmed or considered likely, regulatory action may be necessary and this usually takes the form of an update of the summary of product characteristics and the package leaflet.

Risk Management Plans (RMPs)
(Item 5 of the PRAC agenda)

The RMP describes what is known and not known about the side effects of a medicine and states how these risks will be prevented or minimised in patients. It also includes plans for studies and other activities to gain more knowledge about the safety of the medicine and risk factors for developing side effects.

RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available.

Assessment of Periodic Safety Update Reports (PSURs)
(Item 6 of the PRAC agenda)

A PSUR is a report providing an evaluation of the benefit-risk balance of a medicine, which is submitted by marketing authorisation holders at defined time points following a medicine’s authorisation. PSURs summarises data on the benefits and risks of a medicine and includes the results of all studies carried out with this medicine (in the authorised and unauthorised indications).

Post-authorisation Safety Studies (PASS)
(Item 7 of the PRAC agenda)

A PASS is a study of an authorised medicinal product carried out to obtain further information on its safety, or to measure the effectiveness of risk management measures. The results of a PASS help regulatory agencies to evaluate the safety and benefit-risk profile of a medicine.

Product related pharmacovigilance inspections
(Item 9 of the PRAC agenda)

Inspections carried out by regulatory agencies to ensure that marketing authorisation holders comply with their pharmacovigilance obligations.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/